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Summary 
The development of age-appropriate formulation for children is a challenging task. Children cannot 
easily swallow a conventional tablet, therefore alternative dosage forms that can be administered 
orally are required. These are buccal tablets, oral films as well as orally disintegrating tablets or rapid 
disintegrating tablets. The age-appropriate formulations are contributing enormously to compliance, as 
such formulations ensure acceptable palatability. Therefore, there is a need of suitable excipients. 
Functionalized calcium carbonate (FCC) has already been investigated for different applications. It 
was used to develop orally disintegrating tablets (ODTs) because the tablets were characterized by 
high physical stability at low compressive stress. To ensure acceptable palatability, a taste masked and 
mouthfeel enhanced formulation based on FCC-granules was developed and tested for its acceptance 
in 20 healthy volunteers. This formulation was also analyzed with a novel in vitro model to determine 
rate constants for liquid sorption and disintegration as well as disintegration time. As a further step, the 
stability of the FCC-based granules combined with two model drugs were investigated in form of 
tablets for oral suspension (TOS). The influence of stress conditions on content, disintegration time 
and hardness was assessed. To understand and describe the distribution of drug in different drug loads, 
moxidectin containing mini-tablets were analyzed with synchrotron X-rays micro tomography. 
Moreover, a mineral polymer composite material (FCC-PCL) was developed and investigated for the 
use in geometry constrained sustained release formulation in form of a tablet-in-cup (TIC) device. The 
results show that the FCC-based ODTs with enhanced mouthfeel and taste-masking show good 
acceptability in vivo and the analysis with the in vitro model showed, that the ODTs do not need more 
liquid to completely disintegrate than available in the human mouth. The additional excipient in the 
formulation did not change the characteristics of the FCC under pressure. TOS were found to be stable 
in stress conditions and there was no chemical degradation detected. Humidity and temperature 
affected disintegration time, highlighting the importance of correct storage conditions. It was possible 
to analyze content distribution based on the data obtained from synchrotron X-ray micro tomography. 
The composite material was successfully used in the TIC device providing higher drug load than a 
commercial product by ensuring the same sustained release kinetic. The FCC, with the unique lamellar 
structure on its surface, is able to provide a novel formulation platform based on a ready-to-use 
granule that ensures fast disintegration times, whether formulated in ODTs, TOS or mini-tablets. It 
was also possible to compact mini-tablets with different drug loads. The composite material showed to 
have plastic flow under pressure which is based on the fact that the FCC particles are embedded in the 
PCL. Even though they were exposed to shear stress the lamellae stayed intact and resulted in stable 
compacts, whereas the pure polymer PCL is not compactable. It can therefore be concluded, that the 
microstructure is the key characteristic to the development of age-appropriate as well as compliance 
enhanced formulations. 
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1 Introduction  
1.1 Pediatric patient population 
The pediatric population is classified in five different age groups, these are [1]: 
- Preterm newborn infants (born before 37 weeks of gestational age [2]) 
- Term newborn infants (0 to 27 days) 
- Infants and toddlers (28 days to 23 months) 
- Children (2 years to 11 years) 
- Adolescents (12 years to 16-18 years, dependent on region) 
These age groups are very heterogeneous and therefore each patient needs to be considered as an 
individual [3].  
1.2 Physiological differences of children compared to adults– an overview 
The physiological differences within the age groups are big. Organs such as the liver [4] or kidney 
undergo strong development through the whole childhood. The unique development of the liver is 
among other facts a reason that levels of xenobiotics that are safe for adults can be toxic for children. 
The liver of a neonate has less than 20% of the hepatocytes that are found in the adult liver [4]. The 
kidneys of a newborn have immature renal tubules and also the globular filtration rate is low. This has 
both anatomical and functional immaturity as a root cause [2]. Also the skin is developing heavily, in 
newborns it is much more permeable than in adults [5]. Moreover, the weight to surface ratio is higher 
compared to adults which can lead to systemic toxic effects if exposed to topic xenobiotics [2]. The 
gastrointestinal transit times in newborns can vary highly [6]. Differences in bioavailability are a 
consequence of this (see section Age-appropriate formulations). 
Not only the organs crucial to drug metabolism and absorption are differing from the adult’s situation 
but also organs of perception i.e. ability to taste and ability to smell. In a study where the quantity of 
fungiform papillae and taste pore densities were analyzed, researchers found out that children have 
substantially smaller papillae compared to adults and they have a significantly higher density of 
papillae. This seems to be the reason for the higher sensitivity to sucrose in childhood [7,8].  
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The olfactory function is proven to already be present in neonates, as breastfed infants were reacting to 
the smell of their lactating mother more intensively than to the smell of a lactating mother that was 
unknown to the infant [9]. Even though the newborn seems to be equipped with the ability to smell, 
affective responses to pleasant or unpleasant odors do not present until the child reaches the age of 
5 [10]. 
Newborns have also been found to be able to distinguish sweet taste from non-sweet taste, sour from 
bitter as well as distinguish the aforementioned from salty taste [11]. This was measured by analyzing 
the facial expressions with a facial action coding system adapted to babies (Baby-FACS [11]). 
1.3 Swallowing process of children 
Particularly of interest when talking about oral formulations for children is the development of the 
swallowing process. The swallowing process consists of 3 phases and undergoes some development. 
Phase one is the oral phase, followed by the pharyngeal phase and the esophageal phase. Up to the age 
of 4 to 5 months, the infant is equipped with an extrusion reflex that is responsible for the infant being 
able to only swallow liquids. At the age of 4 to 6 months, the infant can process spoon fed semisolids 
[3]. A gag reflex can last up to the age of 7 to 9. Hence, eating is an active process for the infant and it 
requires the capability to coordinate sucking, swallowing and breathing.  
Therefore, at the age of 4-6 months it is not possible for the infant to swallow a monolithic dosage 
form (such as a tablet or capsule) but using a vehicle like soft food, multi-particulate dosage forms 
might be administered. These multi-particulate dosage forms can be mini-tablets, pellets, powders or 
granules [3]. 
Swallowing difficulties are not only present in children [12], but also in adults [13] and geriatric 
patients [14]. Also, different illnesses can cause so called dysphagia, such as Parkinson’s [15], 
Dementia [16] or Duchenne [17]. Different medication can also cause dysphagia. These are 
anticholinergics, tricyclic antidepressants, theophylline or calcium channel blockers [18] to only name 
some examples. As difficulties to swallow affect patients of all populations, it is important to address 
this problem in the public pharmacy [19] and by developing dosage forms that do not need to be 
swallowed as a whole (see section solid dosage forms). If patients cannot swallow the dosage form, 
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they are prone to crush or manipulate it [20]. In all cases, dysphagia can impair compliance [20,21] 
and effective treatment. 
1.4 Regulatory challenges 
The development of medicines for children faces several challenges as the pediatric population is very 
heterogeneous. Most of the time, there is also a necessity to develop several formulations, meeting the 
needs of different age groups in the pediatric population [22]. This is cost intensive [23]. Moreover, 
industrial companies are not conducting studies about the safety and efficacy in vulnerable populations 
such as pediatric or geriatric patients [6]. Therefore, a new Pediatric Regulation was introduced in the 
European Union in 2007, it includes a Pediatric Investigation Plan (PIP) that describes the drug 
product strategy. This PIP needs to be in accord with the European Medicines Agency’s Paediatric 
Committee (PDCO) at an early stage of development (i.e. latest when the human pharmacokinetic 
studies in adults are completed) [24]. There are different rewards for such a PIP, e.g. EMA allows 
medicines that are authorized in the EU with results from the PIP to have an extension of 6 months for 
the supplementary protection certificate. In the case of an orphan medication, market exclusivity of 
additional 2 years is possible. If the medicine was especially developed for children and already on the 
market in an unprotected state without a patent, the medicine is eligible for pediatric-use marketing 
authorization (PUMA). If the PUMA is conferred, the product profits from 10 years market protection 
[25]. All these incentives should contribute to have more age-appropriate medicines available for 
children. The WHO has compiled a document with literature to consider when developing a pediatric 
formulation, where all aspects are covered [26]. 
In order to get license for medication in children, studies need to be conducted. As we talk about a 
vulnerable population, special guidelines are established [27]. Some of the differences lay in the 
ethical aspect of the trial conduct [28]. The ethical principles are anchored in the Declaration of 
Helsinki, the United Nations Convention on the Rights of the Child, as well as in the Convention for 
the Protection of Human Rights and Dignity of the Human Being with regard to the Application of 
Biology and Medicine [28].  
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Trials in children are considered to be necessary by WHO, as it is the only way to ensure well-being, 
treatment and prevention in children (and all other patient populations). The particular necessity to 
investigate medicines in the vulnerable population of children is recognized by the Directive 
2001/20/EC (i.e. clinical trial directive) whilst ensuring the child’s protection [28]. A large difference 
to the studies in adults is the informed consent. In trials involving children, an informed consent of the 
legal representative is necessary. This consent needs to represent the presumed will of the child and 
can be revoked at any time. Additionally, the minor child needs to receive information that is 
understandable for the child in aspect of the age and developmental stage. This information needs to 
be given by a person experienced with minors and involved in the trial, therefore being fully informed 
about the risks and benefits of it.  
The investigator in the trial has to consider it is also possible at any time throughout the trial, that the 
minor child can form an opinion and express the wish to refuse participation [28]. If possible, age-
appropriate formulations should be used in order to reduce risks such as e.g. choking, and ensure 
accurate dosing. As it is not possible that children can give consent to the participation in studies, the 
use of placebo is more restricted in children compared to studies with adults [28]. 
If there are no trials conducted in children, off-label use and the use of non-licensed products 
continues to be some sort of normal practice.  
Off-label drug use means, that the medicines are used outside of the market authorization (e.g. the use 
of a drug product in children, that is only authorized for adults) [29]. 
Non-licensed drug use means, that the particular product used does not have market authorization (this 
includes compounding or extemporaneous preparations [30]). 
This can lead to adverse events, as the medication has not been studied systematically in children 
[31,32]. In the Netherlands, a study showed, that in 435 patient-days, 90% of the pediatric patients 
received one or more courses of unlicensed off-label medication [33] (in this study unlicensed was 
defined as “medicine modified” or “medicine homemade”). 
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1.4.1 Situation in low and middle income countries 
Medicine availability in low and middle income countries is already a problem for adult patients [34]. 
For children this is equally if not more problematic and has led to the list of essential medicines for 
children (EMLc) by the WHO [35]. These medicines are chosen by a committee that meets every two 
years [36]. The essential medicines on the EMLc are determined to be available in functioning health 
systems in sufficient amounts as well as in the appropriate dosage form in an ensured quality and at an 
affordable price [37]. At the moment, people in low and middle income countries expect medicine to 
be liquid (syrups). This thought needs to be directed in a new way as these liquid formulations (see 
corresponding section) are more expensive and not easy to ship; moreover, some of the medicines 
need refrigeration, which is a problem in these countries [38]. 
1.5 Requirements for dosage forms for children 
1.5.1 Age-appropriate formulations 
An age-appropriate formulation has to fulfill several conditions in order to be considered as such. On 
one hand, there is the pediatric population, where a formulation needs to be properly adjusted [10] but 
there is also the need to do so for the geriatric patient group [6]. The physiological differences are 
most present in very young and very old patients [6]. Hence, it can be stated that accordance with the 
requirements of age-appropriate formulations should be fulfilled in both cases. These requirements are 
adapted from [6]: 
- Sufficient bioavailability (see section “Physiological differences”) 
- Safe excipients (see section “Excipients for pediatric use”) 
- Palatable/acceptable properties (see section “Taste masking”) 
- Accurate and flexible dosing (see section “Liquid dosage forms”) 
- Easy and safe administration (see section “Solid dosage forms”) 
- Socio-cultural acceptability (see section “Rectal formulations”) 
- Technological Manufacturability (see section “Technologies”) 
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1.5.2 Liquid oral dosage forms for children 
There are several liquid formulations available. These are suspensions, solutions, syrups and drops. 
Liquid peroral dosage forms can be swallowed by the children already at young age [10] and they can 
be dosed flexibly to the desired amount [3]. But these formulations have drawbacks such as the 
problem of the stability of the drug [3] and microbiological stability [39] as well as higher costs than 
solid dosage forms [40] and more difficulties to transport them [38]. Moreover, the formulation needs 
to be palatable and dosing consistency has to be ensured [3]. Additionally, there is a risk of over- or 
under-dosing [39]. Another restriction is, that liquid formulations cannot be used in children that suffer 
from an illness that requires restricted intake of liquid [39]. In order to administer liquid formulations 
properly, a dosing device is necessary [3]. Dosing syringes were found to be more accurate than 
dosing cups or spoons [41,42]. But even when using oral syringes, it has been shown that dosing 
inaccuracy can occur when small volumes are used [43]. Drops seem to be a dosage form that can be 
accurately dosed by count, but they also bear the risk of overdosing as shown in a case study [44]. In 
this case, a child died from codeine intoxication due to the fact, that the drop weight of 10 drops varied 
from 494mg to 940mg. The weight of 940mg corresponds to a codeine dose of 23.5mg, which is in the 
toxic range. According to EMA, the correct choice of dosing equipment should depend on the 
therapeutic index of the drug, type, taste of the formulation and ease of administration in practice [10]. 
1.5.3 Solid oral dosage forms 
Classic monolithic oral dosage forms are difficult to swallow for children [6]. Alternative formulations 
that can be administered perorally are buccal tablets [3,45], orodispersible [46,47] or fast dispersible 
tablets [48], soluble tablets [49], chewable tablets [50], sprinkle capsules [47] or “stickpacks” [3,51]. 
Also buccal films [52] and orally dispersible films [53] are counted as alternative solid dosage forms. 
Another alternative is the use of rapid disintegrating tablets (RDT) they can be dispersed or dissolved 
in water prior to administration [54]. 
All these alternative formulations have the advantage that they do not need to be swallowed as a whole 
monolithic dosage form. The mentioned alternative formulations need to be palatable so that the taste 
masking is an additional challenge (see chapter 1.7.2 Taste masking). Such alternative formulations 
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available on the market can be used in the pediatric population provided that there are products 
available in the right dose range.  
1.5.4 Manipulation of existing oral dosage forms 
As most of the time the right dose range is not available, the formulations for adults are 
manipulated [3]. Tablet crushing or opening capsules to be mixed with food is an option but with some 
formulations it can be dangerous when tampering with the dosage form prior to administration [3]. A 
study showed that the bioavailability was reduced by ~45% when Lopinavir/Ritonavir (Kaletra®) 
tablets were crushed to be administered to children compared to the administration of whole 
tablets[55]. 
Most of the time, there is no information about the influence on absorption of the drug, when a tablet 
is crushed [55]. Some substances cause sensitization if in contact with the skin, this can occur after 
crushing a tablet containing e.g. chlorpromazinum [3]. Other substances like finasteride are toxic for 
women which is unsafe for the people in the surroundings, as the active pharmaceutical ingredient 
(API) can be present as an aerosol after crushing [3]. This is due to the fact that the protective coating 
is destroyed when crushed. This can also be disadvantageous when the coating acts as a taste masking. 
There is not only a risk for the person administering the drug but also for the patient. If modified 
release formulations are crushed prior to administration, the kinetics of the designed dosage forms can 
be completely changed. This can lead to a toxic blood plasma level, also called dose dumping [3].  
One way to meet the need of individually dosed medicines is to compound the medication 
extemporaneous for a particular patient or patient groups [30]. These preparations bear some risks as 
they lack data on safety and tolerability as well as pharmacokinetic characterization and bioavailability 
[56] (see section “Regulatory Challenges”). There are even reports of fungal contaminations in 
compounded medicines that lead to infections and deaths [57]. 
There are products available on the market to prepare extemporaneous oral suspensions. These are the 
products ORA-Plus, ORA-Sweet or ORA-Blend [58]. Medicated powders can be suspended in ORA-
Plus or ORA-Blend, whereas ORA-Sweet serves as a syrup vehicle. It has to be taken into account that 
these products contain parabens, which makes them not suitable for neonates and infants [59]. 
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Alternative products are available in Portugal under the name of SUSY-system. These products do not 
contain parabens, propylene glycol or alcohol [60]. 
Administering the dosage form to the child often poses the question whether it can be mixed with food 
and beverages. It is attractive if the mixing contributes to a better palatability of the medicine [3]. 
Most of the time there is only limited information that supports the safety to do so. It is advisable to 
get the information about the influence of food on bioavailability if it exists. It needs to be assessed as 
well, how the medicine reacts to the change of pH when mixed with acidic products (e.g. orange juice) 
or food that is warm [3].  
In England, a guideline (MODRIC) was established for healthcare professionals to provide guidance 
on how to safely deliver reproducible accurate doses to children if manipulation of such is unavoidable 
[61]. 
1.6 Other routes than peroral for administration of drugs– some examples 
1.6.1 Rectal formulations for systemic treatment 
Rectal formulations such as suppositories have some restrictions. They can be advantageous if the 
patient is in a condition where the oral route is not an option as while vomiting or being unconscious 
[3] or in status epilepticus [62]. Moreover, the pre-systemic first-pass metabolism can be circumvented 
when the drug is absorbed trans-mucosal in the rectum [63]. The drug administered rectally to the 
patient does not need to be palatable and hence, taste masking of bitter substances is not necessary [6]. 
But the acceptance of this dosage form can affect compliance because of privacy or cultural reasons 
[63]. In some situations, the ability to retain the suppository can pose a problem. Additionally, the 
correct positioning of the dosage form in the rectum is crucial, because the blood vessels that 
circumvent the first-pass metabolism are not equally present in all sections of the rectum [63]. It was 
shown that dosing with suppositories can lead to inaccurate plasma concentrations in children when 
administering acetaminophen [64]. Moreover, the onset of action is slower in case of acetaminophen 
when administered as a suppository compared to a tablet [64,65]. Hence, for fast acting antipyretic or 
analgesic therapy, a rectal formulation is not always favorable.  
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1.6.2 Formulations to inhale 
Formulations to inhale are the preferred option to treat asthma. In the UK, 10% of the children are 
affected by this condition [3]. Most importantly, the ability to properly inhale the medication needs to 
be taken into account in order to guarantee the clinical effect [66]. To ensure effective treatment, the 
correct inhaler should be chosen. E.g. from birth to 4 years of age, a nebulizer or pressurized metered-
dose inhaler (pMDI) with a valved holding chamber (VHC) and a facemask should be used. Only 
above 13 years of age all devices (also dry powder inhalers and breath-actuated pMDI) can be used. 
As an interface to inhale, a facemask is recommended for children under 4 years of age, whereas older 
children can use a mouthpiece [66]. The dose that is inhaled by the child can be influenced by device 
[6,67] and by the chosen spacer [67]. A thorough instruction for inhalation devices is necessary to 
ensure proper handling as many children apply an incorrect technique [68]. 
1.6.3 Administration of drug via skin 
The stratum corneum of the skin is functional at the time of birth. However, the skin of a term 
newborn is more hydrated and perfused than the adult skin. In preterm newborns, the skin barrier is 
not efficient, this can lead to undesired uptake of substances. The large body surface to body mass 
ratio (cm2/kg) [69] and the reduced volume of distribution lead to enhanced absorption [3]. 
Transdermal drug delivery can generally be considered as route of administration, but the product 
available cannot be easily adapted to the need of an infant, which causes a limitation of use [3,47]. 
1.7 Excipients for pediatric use 
Choosing the fitting excipients for pediatric use is a challenge. Information about safety and risks 
cannot be directly transferred from adults to children. Tools like the ADI (Acceptable daily intake) 
established by the Joint Expert Committee on Food Additives, or PDE (permitted daily exposure), 
created by the ICH (International Conference of Harmonization) for solvent residuals are commonly 
used for risk assessment of excipients in drugs, but the special conditions of other patient populations 
such as physiological differences are not included in these values [6]. Safe excipients for adults have 
been associated with toxicological effects in children [70] (See Table 1). The knowledge about the use 
of excipients in particular age groups is distributed over different sources, therefore US and EU 
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Pediatric Formulation Initiatives (PFI’s) are working together to create a database [70,71]. In this 
database, information about Safety and Toxicity of Excipients for Paediatrics (STEP) is collected.  
The excipient should be inert, non- toxic and if absorbed by the body of a child, it needs to be 
metabolized without toxic effect. Sensitization or allergies should be avoided as well [3]. 
1.7.1 Excipients to be avoided for oral administration 
Some excipients should be avoided in the pediatric population for oral administration, certainly in 
some patient groups. The appropriate selection of excipients depends on the child’s age, condition and 
route of application. A retrospective study showed that critically ill neonates can already be at risk of 
being exposed to toxic levels of benzylalcohol and propylenglycol when administering routine 
medication by continuous infusions [72]. The excipients for the different groups are listed in Table 1 
as well as the adverse reaction that would be caused by the excipient [3]. Most adverse reactions can 
be traced back to the insufficient metabolic capacity in the first month of life [6]. As discussed in the 
section “Regulatory Challenges”, these adverse reactions were not investigated in clinical trials but are 
based on experience and observed cases [32]. 
Table 1: Excipients with higher risk of toxicological effect when administered orally to pediatric population 
adapted from [3]. 
Excipient Adverse reaction 
Neonates and infants younger than 6 months 
Benzyl alcohol Neurotoxicity, metabolic acidosis 
Ethanol Neurotoxicity 
Propylene glycol Seizures, neurotoxicity, hyperosmolarity 
Patients with reduced kidney function 
Aluminum salts Encephalopathy, microcytic anemia 
Propylene glycol Neurotoxicity, hyperosmolarity 
Hypersensitive patients 
Azo dyes Urticaria, bronchoconstriction, angioedema 
Benzalkonium chloride Bronchoconstriction 
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Parabens Allergies, contact dermatitis 
Starches Gluten-induced coeliac disease 
Sulfites, bisulfites Asthma attacks, rashes, abdominal upset 
Patients with metabolic disorders 
Aspartam Phenylketonuria 
Fructose Hereditary fructose intolerance 
Lactose Lactose intolerance, diarrhea 
Sorbitol Hereditary fructose intolerance 
Sucrose Hereditary fructose intolerance 
 
1.7.2 Taste masking 
Oral formulations that are either liquid or swallowed in a dosage form that has no coating, need taste 
masking if the taste is inacceptable. There are several methods to mask the taste, the following 
techniques represent examples. The easiest way is to add sweetener and aroma to a formulation in 
order to cover to the unpleasant taste of an API [73]. Another method is to use physical options, where 
the API is physically hindered by a barrier to be available in the mouth and hence the taste cannot be 
experienced [74]. This includes coated granules or mini-tablet as well as pellets. In order to 
successfully coat such particles, different polymers/lipids are used to prevent dissolution of the drug in 
the environment of the mouth. One option is to use pH-dependent coatings (Eudragit RS30 [74]), that 
do not dissolve in saliva. Another option is to use lipids like Gattecoat®, where naturally derived 
mixed glycerides are applied in a molten stage using fluid-bed process [75].  
Another way that yields successful taste masking is to modify the solubility of the API, so its 
unpleasant taste cannot be detected by the patient. For solubility changing, one can add a substance 
that changes the pH in the microenvironment (e.g. adding an alkalizing agent to a drug that dissolves 
best in acidic conditions). Of course this is only possible if the drug has a pH dependent solubility. 
Another option is to use substances that form a complex with the drug and are therefore not easily 
soluble any longer. Cyclodextrins are the most often used substances [74]. Of course there are even 
more options such as producing solid dispersions by melt extrusion, or spray congealing [74]. As an 
14 
 
alternative it is also possible to create a prodrug of the desired API that is less bitter than the original 
component [73]. 
Taste masking can also be achieved in a biochemical way, where substances interfere with the taste 
receptor or taste transducing mechanism. They obstruct the signal transmitted to the brain so the taste 
signal cascade is blocked [76]. They need to be administered prior to the administration of the drug 
and it is not clear to what extent they are able to affect the aftertaste of a bitter substance. These 
substances have only been tested in a few studies in human [76], and up to the year of 2014, no study 
with children has been conducted [76]. 
1.7.3 Sweeteners 
There are different ways to differentiate sweeteners. The groups of sweeteners can be distinguished 
into the nutritive sweeteners and nonnutritive sweeteners. The first group encompasses all the sugars 
(sucrose, dextrose, fructose, lactose), corn syrup, high-fructose corn syrup and sugar alcohols (polyols, 
e.g. maltiol, mannitol and sorbitol as well as xylitol). The nonnutritive group includes highly intense 
artificial sweeteners such as aspartame or saccharin or intense natural sugars such as glycyrrhizin or 
thaumatin [3]. The sweeteners can also be divided in two groups referred to as bulk and intensive 
sweeteners, respectively [76]. The materials are either natural or artificial. As an example, glycyrrhizin 
is a natural intense sweetener which is nonnutritive [3]. Interestingly, not all the sweeteners are 
approved by the authorities in all countries. For instance, cyclamates are not approved in the US, but 
they are in Canada and the EU. The nutritive sweeteners such as sugars bear the risk to cause caries, 
therefore artificial intensive agents are sometimes more fitting in a formulation as they are used in 
very small amounts (saccharin is 300-500 times sweeter compared to sucrose [76]). Moreover, the 
nutritive sugars are caloric [77] which is not favorable for long-time treatment as well as intake before 
bedtime [3]. Formulations that contain caloric sugars also need to be considered if the patient is 
diabetic. 
1.7.4 Flavors 
Flavors originate from natural and artificial sources. The advantage of natural flavors is the better 
palatability, whereas the artificial flavors are chemically more stable, therefore less batch to batch 
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variability is occurring [76]. Several flavors are available to be used in particular ways, depending 
what character the product has and which condition is treated [10]. 
Acidic basic sensations are proposed to be covered with cherry, lemon, lime, mandarin, orange or 
strawberry; Alkaline basic sensations are suggested to be covered with banana, caramel, cherry, 
liquorice, passion-fruit or peach; Bitter basic sensations are recommended to be covered with cherry, 
chocolate, grapefruit, liquorice, strawberry, peach, raspberry or tutti-frutti; Salty basic sensations are 
proposed to be covered with caramel, grapefruit, lemon, orange or vanilla; and sweet taste is suggested 
to be covered with banana, caramel, cream, chocolate, grape or vanilla [10]. 
Three different conditions can be distinguished and flavors are recommended[10]: 
i) Pain, fever, allergy and infection: Cherry, strawberry, banana, caramel. 
ii) Vitamin deficiency: Blackcurrant, lemon, lime, mandarin, orange 
iii) Indigestion (Antacids): Lemon, lime, orange, peppermint. 
Additionally, there are also geographical preferences present. The US population favors the flavor 
“bubble-gum” and “grape”, whereas “citrus” and “red berries” are the favorites of Europe and 
“liquorice” is the favorite in Scandinavia [10,78]. 
1.7.5 Colorants 
The purpose of colorants in pharmaceutical formulations has its roots in esthetics [56]. They are used 
to make the drug product more attractive or to match the color with the product’s taste (e.g. berry 
flavor with a red color) [3]. There are substances like riboflavin and cupric blue that have intrinsic 
color and are not considered as pharmaceutical colorant and there are synthetic colorants with the 
origin of either plant or mineral [56]. Colorants can bear toxicological risks when used in the pediatric 
population (e.g. azo-colorants). For example, a small amount of iron oxide is more preferable than an 
azo colorant because the oxide is generally considered as non-irritant and non-toxic [79]. The color of 
the drug product is important for identification. The identification is necessary for safety [80]. 
Moreover, the color implicates expectations that may support the therapeutic effect [81]. Using color 
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codes can also be beneficial for the use in countries where it is difficult to educate the patients in a 
written format. 
1.7.6 Palatability testing 
As already described, the palatability is crucial for medication administered to children. Several terms 
are used to describe palatability. For this work, palatability and perception are used as synonyms and 
consist of the components taste and mouthfeel. The latter includes the texture, cooling, heating or 
trigeminal response. Mouthfeel cannot be separated from taste sensation as taste stimuli are 
contributing to a pleasant mouthfeel [82] Palatability is one of the main aspects contributing to the 
acceptability of an oral medication and is determined by the active ingredient and the excipients. 
The investigation of palatability particularly in very young children is challenging [83]. There are 
some options such as a hedonic scale [84], visual analogue scale (VAS) [85], verbal responses [85], 
ranking between products [85], evaluating the ease of administration [86] or registering the 
spontaneous verbal judgement after the child took the medication [84]. The different methods are 
either measured by addressing the question directly to the child or by asking the questions to the 
parents [85]. There are also combinations available, where a VAS is combined with a hedonic scale 
[87]. Another option is to use a hedonic scale and a two-score grouping where specific answers on the 
hedonic scale are related to either satisfactory or unsatisfactory sensation [88]. It is important to ensure 
that the method used is adapted to the age of the child. For example, the hedonic scale to address 
children is considered not to be suitable for children under the age of 3 years [84] and 5 years [89], 
depending on literature. The VAS for parents was already successfully used for children with the age 
of less than a year [90]. There are no international standards so far that could be used as a guideline. 
Even more challenges come with the palatability testing in children. It should be considered that a 
healthy child has a different perception than a child with a certain condition. Ethically it is difficult to 
say whether it is better to do palatability testing in healthy children or in children with the condition 
that will be treated with the medication [83]. Whether it is appropriate exposing a healthy child to API 
even for one dose needs to be assessed [85]. There is also the difference between acceptability and 
preference that needs to be taken into account, as the first describes what can be tolerated and the latter 
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describes what is liked better, this may differ from healthy children to children with a chronic 
condition and the necessity of repeated dosing [85]. Analyzing this differentiation is challenging 
compared to adults, that are trained to do palatability testing [91]. Very young children do also have a 
reduced time span of attentiveness [92] which can mean that the rating will be done by the child but 
may rather be connected to e.g. whether the mother is happy with the kid or whether the child is 
generally in a good mood instead of relating to the palatability of the formulation. Therefore, the 
assessor needs to be specially trained to conduct such studies with children in particular, the assessor 
needs to be competent to exclude external factors that could bias the results [85]. The reproducibility 
of palatability tests is also not a simple task, as there are several options to test for palatability but no 
definite international standard has been identified [82,93]. 
Of course it would be preferable to investigate perception at an early stage of development [24]. As 
mentioned above, human panel tests can be performed but at early stages of development enough 
information about the component is rarely available [24]. To save costs and time, the application of an 
e-tongue is possible to obtain some important data aside from a human panel test [94,95]. The 
electronic tongue is a multisensory device, that can automatically analyze complicated compositions 
based on their characteristics [96]. As the electronic tongue considers aspects of taste it does not allow 
to predict the whole aspects of palatability, therefore human panel tests are still necessary. 
1.8 Compliance 
The topic of compliance is a topic of research on its own. Therefore, for this work only a short 
summary is presented. Compliance is crucial for any medical treatment. It was shown, that children 
die from treatable diseases, because of the lack of suitable formulations. They are incompliant, 
because the medicines available are bitter or impossible to swallow [97]. This pinpoints the necessity 
of age-appropriate formulations (see corresponding section) to ensure compliance. Even the best drug 
cannot be effective, if the palatability is not acceptable. It has also been shown that palatability of a 
treatment is crucial to ensure compliance [87,92]. Also, the esthetics of a dosage form contribute to a 
good compliance [98]. If the color differs in generic drug products, compliance can be negatively 
influenced when switched to another brand of drug [99]. 
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Furthermore, some medication plans are quite inconvenient for children such as the one for Ritalin. 
Therefore, a lot of effort was made to develop a formulation that leads to less intake per day, so 
stigmatization for the child in school to take several capsules per day is reduced [6].  
Another important factor is the ease of administration of medication. If the parent or caregiver is not 
able to give the medication to the child, compliance is reduced [89]. Noncompliance has been 
identified to produce major costs to the health system and also increased morbidity [89].  
This shows, that the medication would be available, but not in the format necessary for children. 
Whether this is ethically justifiable is up for debate. 
1.9 Excipients 
Excipients are used in all formulations and represent a large portion of the dosage form. In solid 
dosage forms excipients are used as fillers, binders, disintegrant, glidants or lubricants to only name 
some of the categories. The excipient needs to be pharmaceutically inert [100]. In the past it was 
shown that the safety was in most of the cases taken for granted but should be researched. Also, 
possible interactions of the API with the excipients need to be taken into account as chemical 
interactions can lead to adverse effects in patients [100]. 
1.9.1 Multifunctional excipients 
Multifunctional excipients form a group of substances that can be used to serve more than one 
function in a formulation. Such an excipient is e.g. starch [101] used as a disintegrant and a binder or 
UICEL that can be used as a binder, disintegrant as well as a filler [102]. There is also Fujicalin which 
can take the role of a filler [103,104] and an excipient to load drugs in it [68]. The same is valid for 
Aerosil (colloidal silicon dioxide), it can be used as a glidant [105] or to be loaded with a drug [106]. 
In the same sense, pellets can be considered a multifunctional excipient as they can act as drug carrier 
[107] and filler because a considerable amount of a multi-unit pellet system consists of pellets [108]. 
Multifunctional excipients are advantageous as they allow to reduce the number of excipients that 
need to be used for a particular formulation [109]. 
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1.9.2 Co-processed excipients 
The creation of co-processed excipients had the goal to combine different advantageous attributes of 
existing excipients and minimize their hindering characteristics. Co-processing is defined as physically 
modifying one or more excipients without changing the chemical properties [110]. These excipients 
represent a beneficial application in direct compaction (see section Technologies). 
Examples for co-processed excipients are Ludiflash® or Pharmaburst [111]. Ludiflash® consists of 
90% mannitol (filler), 5% Kollidon (disintegrant) and 5% polyvinyl acetate (binder) and is supposed 
to be used to formulate orally disintegrating tablets. The advantageous characteristics of this excipient 
are good compressibility, fast dissolution and smooth mouth feeling [110]. 
Pharmaburst consists of mannitol (filler), crospovidone (disintegrant), sorbitol (sweetener), and 
precipitated silicone dioxide (glidant) [112]. It is as well, like Ludiflash®, designed to prepare orally 
disintegrating tablets. 
1.10 Technologies 
To meet the criteria to formulate age-appropriate and compliance enhanced oral formulations, some 
requirements need to be fulfilled. As mentioned above, excipients are an absolute necessity. To 
process those adequately, suitable technologies need to be established. It has been shown, that there is 
a deficit of technologies to develop formulations for children [22]. The ideal requirements for such 
technologies and manufacturing processes should be simple, cost effective and easily scalable. 
There have been some efforts made to develop novel technologies to formulate for children. These are 
e.g. dose sipping with a highly sophisticated straw where the child can sip the dose needed [6]. 
Another innovative device is the nipple shield delivery system (NSDS), that combines a nipple shield 
with an appropriate dosage form to administer drug to the infant while breastfeeding [113]. These two 
examples are rather special and do not fulfill the desired requirements mentioned above.  
1.10.1 Granulation 
If the excipients cannot be directly compacted because they show poor flow resulting in non-uniform 
tablet weight, the excipients can be processed. Different granulation options are standard in 
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pharmaceutical technology. These are e.g. wet granulation and dry granulation. Both processes are 
pursuing the same goal i.e. particle enlargement in a controllable size range. This leads to 
mixtures/excipients that show better flow and less dust. The narrow size range of the particle yields to 
less segregation effect in the end formulation [114]. In wet granulation, the enlargement of the 
particles is achieved by using a spray solution that is sprayed on a powder bed in case of fluid bed 
process or added stepwise to a high shear mixer. In both wet granulation processes, the size 
enlargement of the agglomerated particles (granule) is based on the formation of bridges between the 
particles. High shear granulation is followed by a drying step and if necessary milling step. Both 
mentioned processes are most of the times based on batch production [115,116]. Recent technological 
progresses presented continuous versions of both fluid bed [117] and high shear granulators [118]. 
Another option to granulate in a continuous process is twin screw granulation [119]. Continuous 
processes are easier in scale up and therefore more cost effective. Dry granulation such as roller 
compaction uses force to produce ribbons, that are subsequently milled. Also, this way the particle size 
can be enlarged. One drawback of roller compaction is the dust fraction, that cannot be used. This 
yields higher costs compared to direct compaction where all the material can be used [120]. Compared 
to wet granulation, dry granulation is a faster and therefore cheaper process [114]. It is also suitable for 
moisture or heat sensitive APIs [120]. In the case of roller compaction, it is also a continuous 
process [121].  
1.11 Functionalized calcium carbonate as a novel pharmaceutical excipient 
Functionalized calcium carbonate (FCC) consists of calcium carbonate and tribasic calcium phosphate. 
It has a highly sophisticated surface structure with lamellae and a porous core [122] (see Figure 1). It 
is a highly porous material, that has a surface area of up to ~60m2/g and porosities of approx. 70% 
[122]. The apparent true density is between 2.50-2.73g/cm3 [122]. A study of compaction behavior 
showed, that the compaction of FCC consists of two phases, first the lamellae interlock with each 
other (phase 1), this leads to stable compacts with a high tensile strength at low compaction pressures. 
This interlocking is followed by a densification by fracture of the lamellae and then a plastic 
deformation under higher compressive stress (phase 2) [122]. In previous research, it was shown that 
FCC can be used to prepare orally disintegrating tablets [123] and floating gastro-retentive drug 
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delivery systems [124]. Moreover, it was shown to be used to load drugs into the particle [125] and 
prepare mucoadhesive particles for colonic drug delivery [126]. The differences to ground calcium 
carbonate lay in the morphology of the particle [127].  
 
Figure 1: SEM picture of a FCC particle of batch SO3(a) and SO2 (b). 
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2 Aim  
The main aim of this thesis is to establish new strategies for developing age-appropriate and 
compliance enhanced formulations for children based on the novel excipient FCC. It is of particular 
interest to bridge the gap between technological aspects and therapeutic optimization. Four projects 
were identified to reach this main aim: 
I) Development of an ODT formulation and methods to characterize in vitro disintegration 
kinetics and in vivo acceptability in form of a human panel test. 
II) Studies of stability of FCC-based TOS formulations containing model drugs for BCS1 and 
BCS4 type of drugs. 
III) Establish a method for studying drug-distribution in low-dose formulations on the 
example of moxidectin containing orally disintegrating mini-tablets. 
IV) Development of a mineral-polymer composite material (FCC-PCL) as a multifunctional 
excipient to be used in geometry constrained sustained release formulations. It was the 
aim to reduce the size of the dosage form by compacting it into a Tablet-In-Cup (TIC) 
device. This device can also be beneficial for children. 
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A B S T R A C T
Orally disintegrating tablets (ODT) are comfortable and safe drug delivery methods beneﬁcial for all age groups
of patients. ODTs are characterized by fast disintegration, high physical stability, taste masking and acceptable
mouthfeel. In this work, the applicability of Functionalized Calcium Carbonate (FCC) to formulate ODTs with
enhanced mouthfeel was elaborated and tested for acceptability on twenty healthy volunteers, using a 10-step
visual analog scale Mechanical characteristics of the ODTs were examined using Heckel analysis, modiﬁed
Heckel analysis and Leuenberger equation. Disintegration time was measured with the tensiometer method and
analyzed for disintegration kinetics with a system of ODE. As a result, it was shown that the tablet was well
accepted in healthy volunteers, disintegrated fast in vivo and correlates well with the mathematical model.
Additionally, the compactibility and the physical stability were preserved yielding high porosity to absorb liquid
necessary for disintegration. In vitro disintegration time was successfully linked to in vivo disintegration time.
These ﬁndings lead to the conclusion that FCC is applicable to use in ODT dosage forms and mouthfeel was
successfully enhanced to a pleasant result without losing the unique characteristics of FCC.
1. Introduction
Orally disintegrating tablets (ODT) gain more and more clinical
importance as they can signiﬁcantly improve eﬀectiveness of treatment
for people with dysphagia, acute allergic reactions (Rameesa and
Drisya, 2015), or epileptic seizures (Poukas et al., 2011). ODTs oﬀer the
potential to change the pharmacokinetics of the existing therapies by
reducing ﬁrst-pass metabolism due to a changed absorption site (Rauck
et al., 2009).
The main problem aﬀecting wide application of ODTs is the ne-
cessity of a fast disintegration time, physical stability as well as taste
masking, including an acceptable mouthfeel (Kimura et al., 2015).
Moreover, a cost-eﬀective formulation development and production are
both challenging tasks (Badgujar and Mundada, 2011). ODTs are fa-
vored for applications in pediatrics (Orubu and Tuleu, 2017) and ger-
iatrics (Abdelbary et al., 2005). However, there are challenges. Apart
from manufacturing bottlenecks, the analytics of ODTs are often a
challenge and lack a standardized method for disintegration time and
behavior assessment despite several proposed techniques (Bi et al.,
1996; Morita et al., 2002; Narazaki et al., 2004).
In vitro disintegration testing according to Ph.Eur., allows
assessment of the disintegration time itself without any information
about water uptake or disintegration kinetics. To address this challenge,
several methods have been proposed, e.g., simulated wetting test, where
the time to completely saturate a tablet with liquid is deﬁned as a ta-
blet’s disintegration time (Hooper et al., 2016); the Petri dish method,
where the disintegration time measurement is visually observed (Gohel
et al., 2004); or a texture analyzer method, where the disintegration
time is estimated from a force-displacement proﬁle (Dor and Fix, 2000).
All these methods are highly accurate in registering a time necessary for
a tablet to disintegrate, however they are not suitable for assessment of
kinetics of the weight change in the tablet due to water sorption and
disintegration. A microbalance method, where a tablet is placed on a
grid and immersed into disintegration medium has been reported as
suitable test set up for measurement of kinetic of disintegration
(Stirnimann et al., 2013). In this work this method for disintegration
time measurement and analysis is applied and extended with mathe-
matical model to quantitatively estimate the disintegration kinetics and
liquid necessary for disintegration.
In the publication of Stirnimann et al., along with the microbalance
method to test the disintegration of the ODTs, a novel pharmaceutical
excipient to produce ODT (Stirnimann et al., 2013) was presented. This
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ingredient, called functionalized calcium carbonate (FCC), consists of
co-crystallized calcium carbonate and calcium phosphate. It was shown
to consist of a porous meshwork with a lamellar surface structure
(Stirnimann et al., 2014). Under compressive stress the lamellae in-
terlock to form stable bonds within the tablet while keeping the com-
pact highly porous (Stirnimann et al., 2014). The rough and grainy
appearance of FCC particles suggest that pure FCC may have an un-
pleasant mouthfeel. This may hinder or severely impede an application
of FCC as a main component of the ODT formulations since a good
mouthfeel is of a high importance to ensure acceptability of the medi-
cation (Davies and Tuleu, 2008; Orubu and Tuleu, 2017). Mouthfeel is
strongly connected with taste sensations (Batchelor et al., 2015). The
chalky sensations in mouth left by calcium carbonate and calcium
phosphates may necessitate additional actions to mask this unpleasant
perception. Several options for taste masking are already established in
industry (Douroumis, 2007), such as physical methods (Sohi et al.,
2004), chemical methods (Douroumis, 2007), or admixing of sugars
and aromas (Mennella et al., 2015). Mouthfeel enhancement can be
achieved using substances that create pleasant sensations such as
polyvinylpyrolidone (Metcalf et al., 1998) or eﬀervescent agents e.g.
citric acid in combination with sodium bicarbonate, to complement
taste-masking (Sohi et al., 2004).
This study investigates a suitability and organoleptic acceptance of
FCC as a main component in the enhanced mouthfeel fast disintegrating
ODT formulations, characterized by excellent compactibility and high
physical stability. The organoleptic acceptance of the proposed ODTs
was assessed in an in vivo study with 20 healthy volunteers.
Additionally, the correlation between in vitro measured disintegration
time and in vivo data is presented.
2. Materials and methods
2.1. Granule production
For the production of the granules, Omyapharm FCC 500 OG (co-
crystalized calcium carbonate and calcium phosphate) and Ac-Di-Sol®
(croscarmelose sodium crosslinked, PHEUR) were sieved to<500 μm
fraction. The two excipients were mixed for 10 min with Turbula
blender T2C (W.A.Bachofen, Switzerland) at 34 rpm in a ratio of 97%
Omyapharm and 3% Ac-Di-Sol. This mix was then roller compacted
with Chilsonator IR220 (Fitzpatrick,USA). The agitator was set at
21 rpm speed. The horizontal screw speed was set to 20 rpm. The ver-
tical feed screw speed to 150 rpm. The roll gap was set at 0.5 mm and
the roll pressure was set at 10 bar. The roll speed was set at 3 rpm and
then during the process adapted to speeds between 1.5 rpm and
3.5 rpm. The force on the rolls was between 1.9 kn/cm and 2.2 kn/cm
with corresponding roll thickness of 2 cm. The collected ribbons were
milled with Fitz®Mill Comminutor L1A hammer mill (Fitzpatrick, USA)
using the 1729-0001 type rasping screen (1.5 mm diameter of screen
opening) and hammer at 300 rpm. The resulting granules were sieved
to retrieve the particle size fraction between 180 μm and 710 μm. These
granules are referred to as ReadyMix hereafter in this work. The second
formulation is a mixture composed according to Table 1. This for-
mulation is referred to ODTF hereafter in this work.
2.2. Tablet preparation
The tablets were compacted with Styl’One Classic compaction si-
mulator (Medel’Pharm, France). A Euro B 5 mm ﬂat punch tooling and
a Euro D 11.28 mm ﬂat punch tooling at upper punch immersion depth
of 4 mm were used. The compression cycle consisted of 5 sections: 1.5 s
ﬁlling, 1.5 s upper punch approach, 3.0 s compression, 1.0 s relaxation,
5.0 s ejection. Filling height was set to 20 mm, to allow manual die
ﬁlling; Compaction force was set to 5 kn and 25 kn, respectively.
Tooling lubrication was carried out manually prior to tablet compaction
with magnesium stearate PHEUR (Hänseler, Switzerland).
The tablets were weighed with the balance (Mettler Toledo, AX204,
US). Height and diameter of the tablets were measured using a digital
caliper. The tablets were stored in plastic bags in a plastic box with
desiccant bags (desiccant silica gel, C. Roth AG, Switzerland).
2.3. Compactibility study
A deformation proﬁle was carried out for the ReadyMix and the
ODTF. The compression cycle had the following 5 sections: 2.0 s ﬁlling,
1.5 s upper punch approach, 1.5 s compression, 1.0 s relaxation, 5.0 s
ejection. A ﬂat round Euro D tooling with diameter of 11.28 mm was
used, tooling lubrication was carried out manually using magnesium
stearate PHEUR. Applied compaction pressures were in range from
10 MPa to 350 MPa; the ReadyMix tablets compacted at> 300 MPa
showed a resulting hardness higher than>400N (i.e. greater than
upper detection limit of the hardness tester). Therefore, those tablets
were not analysed, and the proﬁling was carried out for the range of
10–250 MPa. With the ODTF stable tablets were only formed starting at
30 MPa, therefore the proﬁling range for the ODTF is 30–350 MPa.
Compressibility of the two formulations was investigated by ﬁtting
the Heckel equation with experimental data (Eq. (1)) (Heckel, 1961):
⎜ ⎟⎛
⎝ −
⎞
⎠
= +
ρ
k σ Aln 1
1
·
, (1)
where k is the Heckel parameter (MPa−1), σ is the compressive pressure
(MPa), ρ is the density of the tablet (g/cm3), and A is a constant. The
density of the tablet was calculated according to Eq. (2) (Ilkka and
Paronen, 1993):
=ρ m
π r h ρ·
· 1
true
2 , (2)
where m is the mass of the tablet (g), r is the radius of the tablet (cm), h
is the tablet height, and ρtrue is the true density of the material (g/cm3)
measured with Micromeritics AccuPyc 1330,USA. The yield pressure σy
was calculated by taking the reciprocal of the Heckel slope k (Ilkka and
Paronen, 1993) ( =σy k1 ).
The modiﬁed Heckel equation was used to investigate compaction
susceptibility of the material (Kuentz and Leuenberger, 1999):
⎜ ⎟= ⎡
⎣⎢
− − − ⎛
⎝
−
−
⎞
⎠
⎤
⎦⎥
σ
C
ρ ρ ρ ln ρ
ρ
1 (1 )· 1
1rc rc rc , (3)
where σ is the compressive pressure (MPa), C is a constant (MPa−1), ρrc
is the relative critical density, and ρ is the relative tablet density.
Tensile strength was calculated according to Eq. (4).
=σ F
π d h
2·
· ·t , (4)
where σt is the tensile strength (MPa), F is the crushing force (N), d is
the diameter (mm) of the round tablets, and h the height of the round
tablet (mm). Powder compactibility was investigated by plotting tensile
strength as a function of compressive pressures (Leuenberger and
Rohera, 1986).
Deformation of the material under stress and bonding properties of
the material were obtained through compactibility and compression
Table 1
Composition of the ODTF.
Excipient Amount, %
ReadyMix(180 μm− 710 μm) 87.93
Citric acid monohydrate PHEUR 5.71
Sodiumhydrogencarbonate PHEUR 2.86
Sodium cyclamate/Sodium saccharine (10:1) PHEUR 2.5
Orange aroma permaseal (foodgrade) 1
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susceptibility parameters from Leuenberger equation (Leuenberger and
Rohera, 1986).
= − −σ σ e·(1 )t tmax γ σ ρ( · · ) , (5)
where σt is the tensile strength, σtmax is the tensile strength when
compressive pressure (σ)→∞ and relative density (ρ)→ 1, γ is the
compression susceptibility (MPa−1), and σ is the applied compressive
pressure.
Numerical ﬁtting was carried out with Levenberg-Marquardt and
orthogonal distance regression algorithms (Origin Pro 2016).
2.4. Hardness testing
Hardness testing of the tablets was carried out using Dr. Schleuniger
Tablet Tester 8 M (Switzerland) with n = 3 tablets per test.
2.5. Porosity
The porosity was calculated according to Eq. (6). The apparent true
density was measured using helium pycnometer (Micrometrics Accupyc
1330, USA).
⎜ ⎟= ⎛
⎝
− ⎞
⎠
ε m π r h
ρ
1 /( · · ) ·100
true
2
, (6)
where Ɛ is the porosity (%), m is the mass of the tablet (g), r is the
radius of the tablet (cm), h is the height of the tablet (cm) and ρtrue is the
apparent true density (g/cm3).
2.6. Particle size disitribution
Particle size distribution (PSD) was measured using the sieves
90 μm, 125 μm, 180 μm, 250 μm, 355 μm, 500 μm, 710 μm, 1000 μm
on a Retsch Vibro (Schieritz & Hauenstein AG, Arlesheim, Switzerland).
The cumulative passage (%) and the cumulative residue (%) were
plotted and the intersection of both curves was calculated. The x-co-
ordinate of this intersection point yields the median particle size (μm).
2.7. Disintegration measurement
Disintegration time was measured with a Tensiometer K100 (Krüss,
Germany). The grid was further developed from Stirnimann et al. (see
Fig. 1). A 3D printer Formlabs Printer Form 2, Software Preform 2.10.0
was used to print the grid, designed on Solidworks®2016 Sp5.0, using a
black photopolymer resin V2. The grid was immersed in the test liquid
to the level of the notch (see Fig. 1). The measurement was carried out
in demineralized water and artiﬁcial saliva (n = 3). The artiﬁcial saliva
(art. sal.) consisted of 0.228 g/L calcium chloride dihydrate, 1.017 g/L
sodium chloride, 0.204 g/L sodium phosphate dibasic heptahydrate,
0.061 g magnesium chloride hexahydrate, 0.676 g/L potassium carbo-
nate sesquihydrate, 0.273 g/L sodium phosphate monobasic mono-
hydrate and 1 g/L porcine mucin.
First the grid is immersed in liquid, after automatic taring the tablet
is put on the grid. What was measured is the tablet’s net force i.e. the
buoyancy force of the tablet subtracted from the weight force of the
tablet. As we do not consider volume change of a tablet due to swelling
in our model as signiﬁcant, the net force change can be assumed as
linearly proportional to mass change rate.
The water uptake was measured using Tensiometer K100 (Krüss,
Germany). A glass tube, with a ﬁlter paper ﬁxed on the liquid facing
side, was used. The tablet was then placed on the paper prior to im-
mersion in the liquid. After touching the water surface, the weight gain
was registered. The maximal amount of adsorbed liquid was registered
when a plateau was reached.
The total speciﬁc amount of water uptake (g/g) and the total spe-
ciﬁc amount of art.sal uptake (g/g), respectively, were calculated as a
ratio of the individual amount of liquid absorbed by the tablet (g) and
the weight of the individual tablet (g).
2.8. Mathematical model
For a detailed analysis of a disintegration behavior, a mathematical
model based on the system ordinary diﬀerential equations (ODE) was
used. This model describes two processes ongoing during tablet disin-
tegration i.e. water uptake and disintegration. The tablet mass change
rate can be described as a sum of the rate of sorption and disintegration:
= +dm
dt
dm
dt
dm
dt
w d
, (7)
where dm
dt
is the mass change of the tablet per time, dm
dt
w is the wetted
mass change rate of the tablet and dm
dt
d is the disintegrated mass change
rate of the tablet. The change of the rates is shown in Fig. 2.
The diﬀerent rate phases during disintegration can be described
with the corresponding conditions:
Phase A: >dmdt dmdtw d , where the rate is constant and dominated by
liquid sorption; Phase B: =dmdt dmdtw d , where the total rate dmdt is equal to
0; Phase C1: <dmdt dmdtw d , where the disintegration rate is dominant and
this phase can be constant (solid line) or decreasing (dotted line) and
Phase C2: <dmdt dmdtw d , where also disintegration rate is dominating and
the phase can be constant (solid line) or increasing (dotted line).
The system of ODE (Eq. (8)) was numerically solved for mw (t) and
md (t) with Wolfram Mathematica 11.
Also the numerical ﬁtting of the sum of mw (t) and md (t) was ﬁtted
with Wolfram Mathematica 11. The ﬁtted disintegration curve was
diﬀerentiated to obtain the position of an inﬂection point (2nd deri-
vative = 0). The tangent line was calculated for the ﬁtted curve at the
inﬂection point and solved for time at the intersection with the x-axis.
The complete Mathematica workbook is available in Supplementary
material.
The process of sorption and disintegration are described as follows
under the assumption, that only wet solids can disintegrate:
⎧
⎨
⎩
= −
= +
( )λ m
λ m λ m
· 1
· ·
dm
dt w
m
h
dm
dt w d
1
2 3
w w
m
d
(8)
wheredm
dt
w is the wetted mass change rate (g/s), λ1 is the water sorption
rate constant (s−1), mw is the wetted mass of the tablet (g), hm theFig. 1. 3D printed resin grid for disintegration measurement with the tensiometer.
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maximum possible amount of water that can be absorbed by the tablet
(g). The value for hm was determined with water uptake measurements
of the tablet. The dm
dt
d is the disintegration rate (g/s), λ2 the disintegra-
tion rate constant (s−1) and λ3 is the additional disintegration rate
constant (s−1). The λ2 describes how much mass is disintegrating de-
pending on the wetted tablet mass. The λ3 describes the case, where
wetted mass does not immediately disintegrate; this slows down the
process of disintegration. An example ﬁtting to the experimental data is
shown in Fig. 3.
From this numerical ﬁtting the parameters λ1, λ2, λ3 and the
intersection point of the tangent with the x-axis were obtained. This
intersection represents the disintegration time of the tablet (s).
2.9. In vivo disintegration time and mouthfeel assessment
In 20 healthy volunteers (age between 20 and 40), in vivo disin-
tegration time of the 5 mm ODTF tablet was measured with a stop-
watch. Mouthfeel was assessed using 10-step visual analog scale (VAS).
On our VAS the answer 0 represented the most positive answer the
volunteer could choose. This was underlined with icons showing happy,
neutral and sad faces. It was also assessed whether the volunteer was
fasting two hours prior to the study. Eight diﬀerent questions con-
cerning the mouthfeel and taste were asked (Q1–Q8). In Fig. 4 you see
all the questions with the scale and the corresponding possibilities to
answer.
• Do you have a feeling of mechanical roughness in your mouth
(during disintegration)? (Q1)
(0→ not at all rough; 10→ very rough)
• Do you have a feeling of mechanical roughness on your teeth
(during disintegration)? (Q2)
(0→ not at all rough; 10→ very rough)
• Do you have a pleasant feeling in your mouth (during disintegra-
tion)? (Q3)
(0→ very pleasant; 10→ not at all pleasant)
• Does the tablet taste good (generally)? (Q4)
(0→ very good; 10→ not at all good)
• Do you have a dry mouth (after disintegration)? (Q5)
(0→ not at all dry; 10→ very dry)
Fig. 2. Schematic representation of the diﬀerent sections of tablet
mass change during disintegration of an ODT, inset is an example of
experimental data, approximated with smoothing function (thin da-
shed line).
Fig. 3. Example of data measured by the tensiometer method and then ﬁtted with the
model, where the dots are the experimental data, the black line is the tangent and the
dashed line is the modeled function. The arrow indicates the intersection of the tangent
with the x-axis.
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• Do you have an urge to drink (after disintegration)? (Q6)
(0→ not at all; 10→ very much)
• Were there any residues of the tablet remaining in your mouth after
swallowing/spitting out (after disintegration)? (Q7)
(0→ no residues at all; 10→ plenty of residues)
• If yes where? (Q7a)
(tongue, gums, cheeks, teeth, lips, pharynx)
• If a tablet with active substance would taste and feel like this test
tablet, would it be acceptable for you? (Q8)
(0→ absolutely; 10→ absolutely not)
After answering these eight questions the volunteers were invited,
in a form of semi-structured interview, to give their comments about
the sensations experienced while taking the tablets. Volunteers were
free to describe their perceptions in own words. These comments were
recorded in the corresponding section of the questionnaire.
The volunteer was free to choose whether he/she wanted to swallow
the tablet or spit it out. Only volunteers fulﬁlling the following criteria
were accepted to the study: Being non-smoker, not pregnant, do not
take any antibiotic treatment, do not report a known hypercalcemia nor
impaired renal function. Additionally, it was not allowed to participate
if one wears braces or has any dental prosthesis. All volunteers had to
be free of injuries in the oral cavity, not show any inﬂammation in the
mouth or throat, not have a dysphagia nor have any impairment of the
ability to smell and could not show a known allergy to any of the ex-
cipients used.
The protocol for this study was submitted to the local ethical
committee Ethikkommission Nordwest-und Zentralschweiz (EKNZ Req-
2016-00249).
2.10. Statistical data analysis
The data set was tested for normality using OriginPro2016. Pearson
correlation coeﬃcients with 2-tailed test of signiﬁcance, were calcu-
lated for the entire dataset (Q8 was left out, because all volunteers
answered with “0”). Additionally, mode, kurtosis and skewness were
calculated. The gender was assigned to 0 for male and 1 for female,
respectively. For the question about fasting within 2 h prior to the study
0 was assigned to fasting and 1 to non-fasting. Normality test was
performed using Saphiro-Wilk approach with a decision level of 5%.
Analogous to a record of pain sensations, the 10-step VAS can be
divided in 3 subsections depending on a value of the asked aspect (Scott
and Huskisson, 1976): Rather positive sensation (VAS range 0–3.33),
intermediate range (VAS range 3.33–6.66) and rather negative sensa-
tion (VAS range 6.66–10). The asked aspect is rated as favorable if the
values for mode and median lie within a range of 0–3.33. The tablet is
considered as “well accepted” if all the answers are within a favorable
range, i.e. within 0–3.33.
Fig. 4. Scale and possible answers of all the 8 questions in the mouthfeel study.
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3. Results
3.1. Results of the compactibility study
The results of the Heckel, modiﬁed Heckel and Leuenberger analysis
showed comparable results for the ReadyMix and the ODTF, respec-
tively. The standard deviations of the values are below 6% for all
ﬁndings, which underlines consistency (see Table 2).
The Heckel plot showed linear behavior (R2 = 0.975–0.976) for
both formulations. This is a sign of plastic behavior (Ilkka and Paronen,
1993). The σy has been found to be comparable with literature with the
value 363.7 MPa and 443.2 MPa for the ReadyMix and the ODTF, re-
spectively. These values are lower than the ones found in literature for
Calcium Carbonate 330 (σy = 513 MPa) (Stirnimann et al., 2014),
which indicates plastic characteristics of the FCC. The σy for the ODTF
was higher than the one for the ReadyMix, indicating that additional
excipients in the formulation change the plastic deformation behavior
of FCC under compressive stress.
Modiﬁed Heckel analysis shows values for the relative critical
density that are higher than reported in literature 0.226 and 0.285 for
ReadyMix and ODTF respectively, where literature reports 0.125 to
0.154 for pure FCC (Stirnimann et al., 2014). These ﬁndings show that a
stable compact is formed at this density. The values for the relative
critical density of pure powder FCC are slightly lower but still com-
parable, and indicates that compactibility was not reduced compared to
pure FCC.
The results for σmax (13.49–14.01 MPa) are suggesting plastic be-
havior, and the value for γ (2.09–2.83 × 10−3MPa−1) is indicating
brittle behavior according to the suggestion in literature (Leuenberger
and Rohera, 1986). Compared to the values from literature for σmax of
pure FCC (i.e. 8.55–13.92 MPa (Stirnimann et al., 2014)) and σmax of
cellulose (i.e. 12.40 MPa (Stirnimann et al., 2014)) our values show
higher mechanical resistance (Stirnimann et al., 2014). The value for R2
in Table 2 is referred to the ﬁtting of the average curve shown in Fig. 5.
3.2. Results for tablet parameters and in vitro disintegration time
measurements
The ReadyMix granule yielded a median particle size of 522.36 μm.
The apparent true density of the ReadyMix was 2.67 g/cm3 and 2.49 g/
cm3 for the ODTF, respectively.
For both formulations, the high porosity (approx. 35% (v/v)) is
associated with high physical stability (tensile strength about 7 MPa).
The results of the liquid sorption, the absolute amount of liquid, the
disintegration rate and the disintegration time are shown in Table 3.
The sorption rate constant was the highest (0.084 s−1) for the
11.28 mm ODTF tablet absorbing water and the lowest (0.0078 s−1) for
the 5 mm ReadyMix tablet absorbing art.sal. The 11.28 mm tablets are
larger, hence, the absolute amount of water is higher for both for-
mulations. With the height diﬀerence of the tablets (i.e. 1.5 mm height
for 5 mm diameter and 2.8 mm for 11.28 mm), the speciﬁc total liquid
uptake is higher for 5 mm tablets than for 11.28 mm tablets. The 5 mm
ODTF tablet disintegrates slightly slower in art. sal. than in water,
where the ReadyMix 5 mm tablet is 8 s slower in art. sal. than in water.
The constant λ1 increases with tablet size, which is understandable as
the tablet has a larger diameter and height, consequently, a higher
mass. The constant λ2 decreases with increasing tablet size.
3.3. Results of the data analysis from human panel test
With Pearson correlation test, 9 signiﬁcant positive correlations
were identiﬁed, where Pc is the Pearson correlation factor with corre-
sponding p-value (conﬁdence interval of 95%):
• The stronger the roughness was felt in the mouth, the stronger the
roughness was felt on the teeth. (Pc = 0.53; p = 0.017)
• The stronger the roughness was felt in the mouth, the less pleasant
was the feeling in the mouth (Pc = 0.64; p = 0.003)
• The stronger the roughness in the mouth was felt, the worse was the
taste of the tablet (Pc = 0.72; p = 0.000)
• The stronger the roughness was felt in the mouth, the more an urge
to drink was felt (Pc = 0.66; p = 0.002)
• The stronger the roughness on the teeth was felt, the more an urge to
drink was felt (Pc = 0.47; p = 0.038)
• The stronger the roughness was felt on the teeth, the more residues
remained in the mouth after swallowing (Pc = 0.48; p = 0.031)
• The better the taste of the tablet was, the more pleasant the feeling
was in the mouth (Pc = 0.54; p = 0.015)
• The more the volunteer had a dry mouth, the more of an urge to
drink was reported (Pc = 0.45; p = 0.045)
One signiﬁcant negative correlation was found:
• The older the volunteer, the less of an urge to drink was experienced
(Pc =−0.46; p = 0.041)
An interesting correlation was found that shorter disintegration
Table 2
Compressibility and compactibility parameters for ReadyMix and ODTF granulates.
Parameters ReadyMix ODTF
Heckel analysis
k (10−3 MPa−1) ± SDa 2.75 ± 0.05 2.26 ± 0.03
A ± SD 0.435 ± 0.005 0.563 ± 0.004
σy (MPa) 363.70 ± 6.03 443.19 ± 6.36
R2 0.976 0.975
Modiﬁed Heckel analysis
C (10−3MPa−1) 0.820 ± 0.040 0.725 ± 0.008
ρrc± SD 0.226 ± 0.008 0.285 ± 0.001
R2 0.998 0.997
Leuenberger analysis
σmax (MPa)± SD 14.01 ± 0.63 13.49 ± 0.31
γ (10−3MPa−1) 2.83 ± 0.1 2.09 ± 0.11
R2 0.999 0.999
a SD denotes standard deviation.
Fig. 5. The Heckel plot, modiﬁed Heckel plot and Leuenberger plot are shown for the ReadyMix (○) and the ODTF (■) with the corresponding ﬁtting or the ReadyMix (solid line) and the
ODTF respectively (dashed line). The standard deviation was not included for the modiﬁed Heckel plot as the values were<1 MPa.
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time yields stronger feeling of mechanical roughness in the mouth and
on the teeth. Additionally, the shorter the disintegration time, the less
pleasant the feeling in the mouth was and the less pleasant was the
taste.
In Table 4 the mode, variance, kurtosis and skewness are shown for
the age, in vivo disintegration time, fasting in the last 2 h, gender, and
questions 1 to 8 (Q1–Q8).
For all eight questions, the values for the skewness are all positive,
which indicates an overall positive trend for the acceptance of the ta-
blets by the volunteers. The kurtosis of the diﬀerent questions shows
that Q1, Q3 and Q4 are sub-Gaussian distributed and Q2, Q5, Q6 and
Q7 are super-Gaussian distributed. The values in the vicinity of 0 for the
age and the disintegration time show that the data set is normally
distributed. The mode is in Q1 at the value 1 and in all other questions
at 0. This shows that the most frequent answer for Q1 was “1” and for
Q2–Q8 it was “0”. The median and the mode of the answers for all the
eight questions were lower than 3.33, which indicates a tendency of the
answers to group in the range of “rather positive sensation”, i.e. VAS
0–3.33. The values of 1.25 and 1.00 for the median were observed for
answers to Q1 and Q3. The answers in the vicinity to zero are associated
with positive perception.
The mechanical roughness in the mouth (Q1) was reported by one
volunteer as “rather negative sensation” (VAS = 7), by ﬁve volunteers
the intermediate range (VAS 4–5.5) was reported, and fourteen vo-
lunteers rated the feeling in the mouth as rather pleasant (VAS 0–3).
The mechanical roughness on the teeth (Q2) was reported by one
volunteer as rather negative sensation (VAS = 7), two reports are in the
scale of intermediate range (VAS = 4) and seventeen volunteers gave
rather pleasant sensation estimate (VAS 0–3).
The question whether the volunteers have a pleasant feeling in their
mouth (Q3), by one volunteer was answered in the scale of inter-
mediate range (VAS = 4) and nineteen volunteers gave rather positive
sensation estimates (VAS 0–3).
The general taste assessment of the tablet (Q4) by all volunteers the
rather positive sensation estimate was given (VAS 0–3).
The dry mouth sensation (Q5) was reported by two volunteers as
intermediate (VAS 4–5) and eighteen volunteers gave it a rather posi-
tive sensation estimate (VAS 0–3).
The urge to drink (Q6), was reported as intermediate (VAS 5–6) by
two volunteers and eighteen volunteers indicated a rather positive
sensation (VAS 0–3).
The residues in a mouth (Q7) were rated as intermediate by one
volunteer, nineteen volunteers rated the residues in a mouth as a rather
positive sensation (VAS 0–3).
The last question (Q8) about the acceptability of the test tablet all of
the 20 volunteers answered with “absolutely acceptable” estimate
(VAS = 0). This underlines the enhanced mouthfeel and acceptable
taste.
In Table 5 the results of the normality test are shown. For age and in
vivo disintegration time, the normality cannot be rejected, whereas for
questions Q1–Q7 normality is rejected at the decided level of 5%. Q8
was excluded from analysis (all values were equal to 0).
The age and the in vivo disintegration time in the cohort were dis-
tributed normally which shows a representative group of volunteers.
These ﬁndings are supported by the values of kurtosis that are close to
0.
Table 3
The tablet parameters of the investigated formulations, sorption rate constants, absolute amount water/art. sal. uptake, in vitro disintegration time in water/art. sal. of the ReadyMix and
the ODTF for 5 mm and 11.28 mm tablets. In vivo disintegration time for the ODTF is shown as well. The R2 values for all the ﬁtted curves were between 0.981 and 0.999.
ReadyMix 5 mm ODTF 5 mm ReadyMix 11.28 mm ODTF 11.28 mm
Height (mm) ± SDa (n = 12) 1.53 ± 0.05 1.55 ± 0.02 2.82 ± 0.01 2.93 ± 0.02
Diameter (mm)± SD (n = 12) 5.04 ± 0.00 5.04 ± 0.00 11.36 ± 0.00 11.36 ± 0.01
Weight (mg)± SD (n = 12) 52.3 ± 1.4 51.6 ± 0.7 502.2 ± 2.5 499.6 ± 2.4
Porosity (%) ± SD (n = 12) 35.58 ± 0.68 33.04 ± 0.54 34.16 ± 0.22 32.38 ± 0.40
Tensile strength (MPa)± SD (n = 3) 8.00 ± 0.38 6.27 ± 0.46 8.05 ± 0.06 5.69 ± 1.41
Water sorption rate constant λ1 (s−1)± SD (n = 3) 0.0134 ± 0.0045 0.0269 ± 0.0149 0.0580 ± 0.0103 0.084 ± 0.0201
Absolute water uptake (g)± SD (n = 3) 0.26 ± 0.02 (after 70 s) 0.32 ± 0.02 (after 100 s) 1.40 ± 0.05 (after 80 s) 1.11 ± 0.08 (after 250 s)
Total speciﬁc amount of water uptake (g/g) 5.08 ± 0.36 6.14 ± 0.32 2.78 ± 0.1 2.22 ± 0.15
Disintegration rate constant λ2 in water (s−1) ± SD (n = 3) 0.4086 ± 0.1361 0.6054 ± 0.3504 0.1603 ± 0.0356 0.2543 ± 0.0130
Disintegration time in water (s) ± SD (n = 3) 10.23 ± 1.02 11.44 ± 0.90 26.11 ± 0.55 21.04 ± 1.96
Sorption rate constant λ1 in art. sal (s−1) ± SD (n = 3) 0.0078 ± 0.0017 0.0228 ± 0.0089 0.0468 ± 0.0110 0.0766 ± 0.0152
Absolute art. sal. uptake (g) ± SD (n = 3) 0.34 ± 0.02 (after 90 s) 0.28 ± 0.03 (after 60 s) 1.24 ± 0.06 (after 100 s) 0.99 ± 0.11 (after 250 s)
Total speciﬁc amount of art. sal. uptake (g/g) 6.52 ± 0.38 5.39 ± 0.54 2.46 ± 0.12 1.98 ± 0.22
Disintegration rate constant λ2 in art. sal. (s−1) ± SD (n = 3) 0.2457 ± 0.045 0.5190 ± 0.1867 0.1299 ± 0.0328 0.2207 ± 0.0043
Disintegration time in art. sal. (s) ± SD (n = 3) 18.92 ± 2.76 13.49 ± 0.7 24.15 ± 3.17 21.67 ± 0.74
In vivo disintegration time (s) ± SEb (n = 20) – 22 ± 2 – –
a SD denotes standard deviation.
b SE denotes standard error.
Table 4
The diﬀerent statistical values of the assessed questions and the age, in vivo disintegration time, fasting within the last two and sex are shown with a conﬁdence level of 95%.
Mean Standard Error Median Mode Sample Variance Kurtosis Skewness Conﬁdence Level
Age 29.250 0.912 29.500 31.000 16.618 0.205 0.639 1.908
Disint.time 22.407 1.646 21.550 25.200 54.215 −0.020 0.377 3.446
Food in 2h 0.550 0.114 1.000 1.000 0.261 −2.183 −0.218 0.239
Gender 0.600 0.112 1.000 1.000 0.253 −2.018 −0.442 0.235
Q1 2.350 0.480 1.250 1.000 4.608 −0.664 0.779 1.005
Q2 0.975 0.436 0.000 0.000 3.802 4.031 2.124 0.913
Q3 1.225 0.273 1.000 0.000 1.486 −0.313 0.745 0.571
Q4 0.550 0.153 0.000 0.000 0.471 −0.240 0.887 0.321
Q5 0.800 0.321 0.000 0.000 2.063 3.682 2.046 0.672
Q6 0.950 0.394 0.000 0.000 3.103 3.582 2.074 0.824
Q7 0.875 0.261 0.500 0.000 1.365 1.508 1.435 0.547
Q8 0 0 0 0 0 – – 0
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In Fig. 6 the volunteers’ answers to the 8 questions are shown. The
results have a trend towards 0, which is underlined by the positive
values for skewness. This indicates that the values for the answers are
lower than the mean value. For Q7, ten volunteers answered that there
were residues remaining after swallowing the tablet. Residues were
reported in Q7a to be on the tongue (n = 4), on the teeth (n = 3), on
the gums (n = 4) on the lips (n = 1) and in the cheeks (n = 1). One
volunteer answered that there were residues, but did not indicate where
they were located
The results of the semi-structured interview, where the volunteers
were free to describe their perceptions in the mouth while taking the
tablet, show that some of the volunteers described the feeling of the
disintegrating tablet as nice, sparkly and tickly. There were no negative
nor natively-tinted descriptions given by any of the volunteers.
4. Discussion
The results for Heckel analysis, modiﬁed Heckel analysis and
Leuenberger analysis in Table 2 (i.e. σmax and γ) indicate plastic and
brittle behavior (Leuenberger and Rohera, 1986). Therefore, we show
that the unique compaction properties of the FCC are preserved in
formulations with other components. The addition of mouthfeel en-
hancing excipients had no signiﬁcant impact on the mechanical prop-
erties of compacts. These ﬁndings are highly encouraging as they sup-
port a formation of stable tablets at rather low compaction pressures
while keeping a high porosity to absorb liquid (Stirnimann et al., 2013,
2014).
From the results of the tablet properties, we see that tablets have
high physical stability (tensile strengths are between 5.7 and 8.1 MPa)
compared to pure FCC that shows a tensile strength of about 8 MPa at
the same compaction pressure (Stirnimann et al., 2014).
The porosity of the four diﬀerent tablets was between 32% (v/v)
and 36% (v/v), which are higher values than reported in literature on
ODTs produced with other substances (Schiermeier and Schmidt,
2002). This result is solely associated with FCC performance, which
yields tablets with high porosity and high physical stability (Stirnimann
et al., 2013). These material characteristics seem to be preserved in the
ReadyMix granules and in the ODTF. For ODT production, the
ReadyMix and the ODTF are better suitable due to lower bulk volumes
and better ﬂowability when compared to pure FCC powder.
The results in Table 3 show that ODTF tablets take up water faster
and disintegrate quicker than the ReadyMix tablets. This is associated
with citric acid and sodium bicarbonate reaction in presence of
moisture.
The total speciﬁc liquid uptake is dependent on tablet volume. The
results show, that the disintegration time is independent of the nature
of the disintegration medium. In both media, the disintegration was
within 30s.
The sorption rate constants and the disintegration rate constants (λ1
and λ2) depend on the tablet geometry and are invariant to formulation
diﬀerences. Therefore, the mechanism of liquid sorption and disin-
tegration is similar in water and art. sal., thanks to the governing role of
the FCC.
The results show that large amounts of liquid are taken up by the
tablets. This comes from the ﬂow into the porous media combined with
the swelling capacity of croscarmelose sodium (Zhao and Augsburger,
2005, 2006). Due to the swelling eﬀect, a disintegrant component is
enlarging the capillary volume and therefore, more water can be ab-
sorbed (Washburn, 1921). This observation can be underlined with the
ﬁndings of (Stirnimann et al., 2013) for FCC-based ODTs. The measured
sorption and disintegration rates, as well as speciﬁc liquid uptake are
indispensable to develop eﬃcient and palatable ODTs. Total liquid
availability in a human mouth is an important factor and the amount of
liquid needed to disintegrate an ODT must not exceed this value.
In Table 3, the results of liquid uptake experiments with art. sal.
suggest that a necessary volume of 0.28 ml for 5 mm ODTF tablets is
necessary to disintegrate these tablets. This volume is easily available in
an adult human mouth. In literature, the unstimulated saliva ﬂow rates
are reported to be of 0.3 ml/min (Porter et al., 2004). In children and
young adults (3–16 years) values of 0.4 to 0.51 ml/min are reported
(O’Sullivan and Curzon, 2000). It has to be considered, that with sen-
sations of taste, the salivary ﬂow is stimulated, as well as while chewing
or eating. Moreover, citric acid has been reported to generate the lar-
gest salivary ﬂow production when used as a stimulant (Carpenter,
2013). The literature reports here a stimulated salivary ﬂow of 4–5 ml/
min (Porter et al., 2004) and for children and young adults (3–16 years)
of 1.08 to 1.21 ml/min (O’Sullivan and Curzon, 2000). For patients
suﬀering from xerostomia, the stimulated salivary ﬂow is also suﬃcient
to disintegrate the tablet completely (0.7 ml/min (Anabel et al., 2016)).
The results of the in vivo study show that disintegration time is
measured to be 22.41 ± 1.65 s (SE), which is very reasonable for the
patient. This value is not far from the in vitro data for the disintegration
time (13.49 s).
In order to formulate ODTs that disintegrate in predictable time in
vivo, the mechanism of disintegration has to be known. In this respect, a
correlation between λ2 obtained in vitro and in vivo needs to be estab-
lished. We propose a correlation factor of 0.95 for 5 mm ODTF tablets.
Application of this factor leads to prediction of in vivo disintegration
time 10 s slower than in vitro. We expect this correlation factor to be
smaller for 11.28 mm ODTF tablets (approx. 0.85). For larger
Table 5
The results for a normality test with p-value and the decision at the level of 5%.
Statistic of Normality
test
p-value Decision at level(5%)
Age 0.94519 0.29994 Can't reject normality
In vivo disint.time 0.97765 0.9003 Can't reject normality
Q1 0.87118 0.01232 Reject normality
Q2 0.58192 1.92E-06 Reject normality
Q3 0.86907 0.01132 Reject normality
Q4 0.73884 1.21E-04 Reject normality
Q5 0.63405 6.77E-06 Reject normality
Q6 0.61808 4.56E-06 Reject normality
Q7 0.76203 2.47E-04 Reject normality
Fig. 6. Histograms with the answers given by 20 healthy volunteers to all eight questions.
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geometries, the surface diﬀerence becomes important in a constrained
environment such as a human mouth. For the ReadyMix tablets, where
CO2 formation does not take place, this correction factor remains equal
to 0.95.
The answers to the eight questions are rated as pleasant since the
median and the mode are in a lower range of VAS (≤3.33). Therefore,
we can speak of a tablet as being well accepted by the volunteers. The
answers to questions 1 show that the volunteers felt the particles, by
reporting a rough sensation in the mouth (mode and median were 1 and
1.25, receptively), however it was not rated as an unpleasant sensation
(Answers to Q3, mode and median were 0.00 and 1.00, respectively)
This ﬁnding is not surprising as humans are able to detect particles sizes
of about 5 μm (Guinard and Mazzucchelli, 1996).
The results of the correlation study show, that all positive correla-
tions follow logical assumptions e.g. when the roughness in the mouth
increases, the roughness on the teeth increases as well.
The good acceptability of the ODTF tablets root in the addition of
sweetener and aroma as well as the citric acid in combination with
sodium bicarbonate. The sodium saccharine and the sodium cyclamate
have a high sweetening power therefore only little amounts are ne-
cessary to reach pleasant sweetness (Sodium saccharine is 300–600
times sweeter than sucrose (Rowe et al., 2009)). The orange aroma is
reported to be well acceptable (Strickley et al., 2008), also used in
pediatric formulations, and combining well together with the citric
ﬂavor of the citric acid. The combination of citric acid and sodium bi-
carbonate is used in eﬀervescent tablets (Jacob et al., 2009). In our
formulation, it created a tickly, fresh sensation that was positively ex-
perienced by the volunteers.
5. Conclusion
The results of our study show that FCC is a suitable material for
proposed ODT formulations without any unpleasant sensation in the
mouth. The proposed ODT formulations preserve high physical stabi-
lity, thanks to good compactibility properties of FCC, and feature a fast
disintegration time. With our proposed model for analysis of experi-
mental data, we observed that the amount of saliva necessary to com-
pletely disintegrate a tablet is available in the mouth of adults. With the
results of the palatability study, we show good acceptance of FCC-based
ODT formulation in healthy volunteers. These ﬁndings make the pro-
posed formulation strategy very appealing to be used in further de-
velopment of age-appropriate ODTs.
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ABSTRACT
Tablets for oral suspension (TOS) present a convenient alternative dosage form to conventional tablets.
Dispersed in a glass of water or on a spoon, such tablets can be easily administered, which can become
beneficial for pediatric or geriatric patients. The novel excipient functionalized calcium carbonate (FCC),
consisting of calcium carbonate and calcium phosphate, has already shown to be suitable to produce
orally disintegrating placebo tablets. In this study, the influence of formulation composition on disintegra-
tion time in water and artificial saliva was investigated using caffeine and oxantel pamoate as model
drugs, reflecting BCS class 1 and BCS class 4, respectively. The optimized formulation for each model drug
underwent a stress test. The results show that the drug content in DTs was not influenced by FCC under
stressed conditions, however the disintegration and dissolution performance was affected by temperature
and humidity. It can be concluded that it was possible to produce TOS characterized by rapid disintegra-
tion complemented by high physical stability of the tablets and chemical stability of the drug.
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Introduction
Excipients used in formulation development of solid dosage
forms need to fulfill several characteristics to be used as such
[1]. For solid dosage forms, these include chemical stability,
good compactibility, good flowability and absence of any
remarkable pharmacological effect. Differences from excipient to
excipient are not solely material based but can also differ in
particle size or surface morphology. Microcrystalline cellulose
and cellulose nanofibers are basically the same from the chem-
ical point of view, but differ strongly in terms of morphology
[2]. For some applications, the particle surface morphology is
essential as, e.g. for the delivery of the drug substance
Pranlukast in dry powder inhalators using different types of lac-
tose [3]. When the characteristic of the excipient is mainly
based on its surface morphology, it is essential that this surface
structure is not influenced by the drug substance itself [4].
Surface morphology can also reflect porosity of the material,
therefore contribute to the facilitated ingress of water, which is
essential for fast disintegrating formulations [5]. Excipients with
high specific surface are often used in formulations requiring
rapid liquid ingress, wherever the high contact surface should
not become a promoter of drug degradation in the tablets [6].
An important advantage of tablets for oral suspension (TOS) is,
that they can be dissolved or dispersed in water prior to adminis-
tration to form either a suspension or a solution [7]. This makes
TOS very convenient dosage forms which offer a possibility of
high dose administration without having to swallow a monolithic
dosage form [8] when dispersed in a glass or disintegrated on a
spoon. This can be advantageous for special patient groups like
pediatrics and geriatrics [9]. For TOS – the same is valid for orally
disintegrating tablets (ODTs) – a rapid disintegration is crucial
[10,11]. Moreover, applying manufacturing methods that are cost
effective is a necessity [12]. Therefore, a deep understanding of
the influence of different factors on disintegration time facilitates
formulation work for TOSs [13]. It should be noted that taste is an
essential factor for tablets for oral suspension to ensure patients’
compliance. Previous research show that FCC based dispersible
tablets are well accepted with taste enhancement components,
such as artificial sweeteners and aromas [14]. To exclude any
potential influence of taste enhancement excipients on model
drug stability in presence of FCC, the formulations investigated in
this study were simplified.
Functionalized calcium carbonate (FCC) is a novel pharmaceut-
ical excipient that can be compacted into stable compacts at rela-
tively low compressive pressures. It is highly porous, with lamellar
surface structure [15] and can be used to produce orally disinte-
grating tablets [16] along with gastroretentive formulations [17]
and colonic drug delivery formulations [18]. The lamellar structure
of the FCC particles is very rigid, featuring high resilience to
mechanical stress, such as compression or shear stress in hot melt
extrusion process [19]. This lamellar structure of the FCC particles
is responsible for high specific surface and porosity of the individ-
ual particles, thus accountable for higher contact surface between
drug and excipient particles. Therefore, it is essential to investigate
the potential influence of the drug on the stability of the TOS for-
mulations with FCC.
In this work, the influence of drug, humidity, and temperature
on FCC-based TOS characteristics was investigated. The results on
drug content, hardness, and disintegration time in water and in
artificial saliva (art.sal.) after accelerated stress test were obtained
for hydrophilic model drug caffeine (BCS class 1) and the hydro-
phobic model drug oxantel pamoate (BCS class 4).
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Materials and methods
Materials
For tablet preparation, caffeine (Sandoz, Switzerland) and oxantel
pamoate (Megafine, India) as well as FCC S02 (OM2501, Omya
International AG, Switzerland) and the Croscarmellose Sodium
(AcDiSol, FMC, USA) were used. For the analysis of disintegration
time, demineralized water and artificial saliva was used. The artifi-
cial saliva was composed of calcium chloride dihydrate, sodium
chloride, sodium phosphate dibasic heptahydrate, magnesium
chloride hexahydrate, potassium carbonate sesquihydrate, sodium
phosphate monobasic monohydrate, and porcine mucin. All used
chemicals were of analytical grade purchased from Sigma-Aldrich
(St. Louis, MO, USA)
For HPLC analysis of caffeine samples, acetonitrile (Carl Roth,
Germany) was used. For samples containing oxantel pamoate N,N-
dimethylformamid (Carl Roth, Germany), a 42:58 (v/v) mixture of
acetonitrile and formate buffer was used. All samples were filtered
through 0.45mm PTFE filter (Wicom, Germany) prior to
the analysis.
For the different conditions in stability test NaCl solution was
prepared for the 73–78%RH and saturated LiBr solution for a rela-
tive humidity of 5–10%.
Dissolution tests were carried out in 1000ml of simulated gas-
tric fluid (0.1 N HCL, Carl Roth, Germany) for caffeine samples and
in simulated gastric fluid with 1% (w/v) cetyltrimethylammonium
bromide (CTAB) for oxantel pamoate tablets.
Methods
Preparation of the tablets and powder mixtures
The drug substances caffeine (Sandoz, Switzerland) and oxantel
pamoate (Megafine, India) were sieved to obtain the size fractions
below 500 mm. The tablet compositions are shown in Table 1 and
follow the 3-factor, 2-level escribed central composite design
(CCD) multiplied by trivial single-factor design (Stavex, AICOS,
Switzerland) with mixture factors constraint. As factors for CCD
the croscarmellose sodium concentration, drug load, and FCC con-
centrations were used. The CCD was multiplied by single-factor
(drug type) design, where drug type was varying between caffeine
and oxantel pamoate. The complete design is shown in Table 1,
star points correspond to formulations 1, 2, 3, 4 and 5, 6, 7, 8 for
caffeine and oxantel pamoate, respectively. Central points corres-
pond to positions 9 and 10 for caffeine and oxantel pamoate
respectively. Regression model used to create the response sur-
face includes quadratic interactions. Response of disintegration
time in artificial saliva has been transformed with y2 function.
Prior to blending with drug powder, the FCC S02 (OM2501,
Omya International AG, Switzerland) and the Croscarmellose
Sodium (AcDiSol, FMC, USA) were dry granulated by roller com-
paction process (Figure 1).
In order to obtain placebo granules, the FCC and
Croscarmellose Sodium powders were sieved <500 mm and
blended together at the variable ratios (Table 1) for 10min in a
powder blender (TurbulaT2C, Basel, Switzerland) followed by roller
compaction with Chilsonator IR220 (Fitzpatrick, Elmhurst, IL, USA).
Rolls pressure was set to 10 bars, rolls gap was kept at 0.5mm.
The vertical and horizontal feed screws were operated at 150 rpm
and 20 rpm, respectively. The resulting ribbons were milled at
300 rpm with the FitzVRMill comminutor L1A (Fitzpatrick, Elmhurst,
IL. USA) using hammer mill setup with 1.5mm diameter screen.
The granule size fraction between 180 mm and 710 mm (Retsch
Vibro, Schieritz&Hauenstein AG, Arlesheim, Switzerland) was used
in all further formulations [14].
Tablets for oral suspension were produced by tableting the
powder blends of an active pharmaceutical ingredient (API) and
the granulates at variable ratios according to Table 1.
According to the optimal formulations, powder mixes were
prepared in order to see potential impact of roller compaction on
the performance of the TOS.
Tablet preparation
Styl’One Classic compaction simulator (Medel’Pharm, France)
equipped with Euro D 11.28mm flat round tooling with upper
punch immersion depth of 4mm was used for compaction of all
formulations in this study. The compaction cycle consisted of five
sections: 1.5 s filling, 1.5 s upper punch approach, 3.0 s compres-
sion, 1.0 s relaxation, 5.0 s ejection. Variable compressive force
Table 1. Compositions of screening formulations, optimized formulations and the formulations undergoing stress test.
Screening Drug type Disintegrant concentration (%) Drug load (%) FCC concentration (%)
1 Caffeine 5.49 17.32 77.19
2 Caffeine 17.51 17.32 65.17
3 Caffeine 5.49 52.68 41.83
4 Caffeine 17.51 52.68 29.81
5 Oxantel pamoate 5.49 17.32 77.19
6 Oxantel pamoate 17.51 17.32 65.17
7 Oxantel pamoate 5.49 52.68 41.83
8 Oxantel pamoate 17.51 52.68 29.81
9 Caffeine 11.50 35.00 53.50
10 Oxantel pamoate 11.50 35.00 53.50
11 Caffeine 3.00 35.00 62.00
12 Caffeine 20.00 35.00 45.00
13 Caffeine 11.50 10.00 78.50
14 Caffeine 11.50 60.00 28.50
15 Oxantel pamoate 3.00 35.00 62.00
16 Oxantel pamoate 20.00 35.00 45.00
17 Oxantel pamoate 11.50 10.00 78.50
18 Oxantel pamoate 11.50 60.00 28.50
Optimal formulations Caffeine 5.2 18.7 76.1
Oxantel pamoate. 5.2 18.7 76.1
Formulations undergoing stress testa,b Caffeine 5.2 18.6 75.7
Oxantel pamoate 5.2 18.6 75.7
aAll the formulations contained 0.5% magnesium stearate <500 mm.
bThe same granule as in the formulation undergoing stress test was used as a placebo formulation.
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from 6 kN to 10 kN was used to obtain a tablet hardness range
within 90 to 120N. The punches were manually lubricated with
magnesium stearate (Sandoz, Switzerland) prior to compaction.
Obtained tablets were stored in a desiccator under dry conditions
prior to the analysis.
Hardness testing
Tablet hardness (N¼ 3) was tested using Dr. Schleuniger Tablet
Tester 8M (Pharmatron, Switzerland) immediately after
tablet compaction.
Disintegration time measurement and analysis
In vitro disintegration time was analyzed from disintegrating tab-
let net force plot versus time registered with Tensiometer K100
(Kr€uss, Germany) equipped with a custom-made tablet holder. In
details, the method is described in [14]. Tests were carried out in
35ml of water or artificial saliva. The disintegration volume of
35ml is required to accommodate the tablet holder grid used in
the selected method for disintegration assessment [14,16]. This
amount of liquid is not representative for the situation in a human
oral cavity, however it provides sufficient, yet not excessive,
amount of liquid to ensure disintegration and sufficient discrimin-
ation between studied formulations.
The composition of the artificial saliva was: 0.228 g L–1 calcium
chloride dihydrate, 1.017 g L–1 sodium chloride, 0.204 g L–1 sodium
phosphate dibasic heptahydrate, 0.061 g L–1 magnesium chloride
hexahydrate, 0.676 g L–1 potassium carbonate sesquihydrate,
0.273 g L–1 sodium phosphate monobasic monohydrate, and
1 g L–1 porcine mucin. Net force was registered until the tablet
was completely disintegrated. The obtained curves were used to
numerically fit the system of linear ODE (ordinary differential
equations) model (Equation (1)) and analyzed for the sorption rate
constant (k1, s
1), the disintegration rate constant (k2, s
1), the
additional disintegration rate constant (k3, s
1), and the disinte-
gration time [14].
dmw
dt
¼ k1  mw 1mwhm
 
dmd
dt
¼ k2  mw þ k3  md
;
8><
>:
(1)
where dmwdt describes the wetted mass change rate (g s
–1); k1 rep-
resents the liquid sorption rate constant (s1), mw is the wetted
mass of the TOS (g), hm is the maximum possible amount of test
liquid that can be absorbed by the TOS (g). The dmddt is defined
the disintegration rate (g s–1), k2 is the disintegration rate con-
stant (s1), and k3represents the additional disintegration rate
constant (s1). The constant k2 illustrates how much mass is disin-
tegrating depending on the wetted tablet mass. The constant k3
represents the case where wetted mass does not immediately
leave the tablet surface; this slows down the process of disintegra-
tion by increasing a liquid sorption path length.
Drug content analysis
The content of caffeine and oxantel pamoate was analyzed chro-
matographically with Shimadzu Nexera 2 uPLC system with soft-
ware LabSolutions Lite Version 5.82. For analysis of caffeine
samples, an adapted method of Ph.Eur. 7.6 was used [20].
The tablet and powder samples were prepared by dispersing in
100ml and 50ml, respectively, of 50:50 (v/v) mixture of aceto-
nitrile (Carl Roth, Germany) and water. Aliquots of 750ml and
500 ml of dispersion for tablet and powder samples, respectively
were diluted with 10ml of 50:50 (v/v) mix of acetonitrile and
water. All samples were filtered through 0.45 mm PTFE filter
(Wicom, Germany) prior to the analysis. An amount of 20 volumes
of tetrahydrofuran (Merck, Germany), 25 volumes of acetonitrile
and 955 volumes of a solution containing 0.82 g L–1 of sodium
acetate (Carl Roth, Germany) adjusted to pH4.5 with glacial acetic
acid (H€anseler, Switzerland) were mixed and used as mobile
phase. The flow rate was set to 1ml min–1. As a stationary phase
the SymmetryVR C18, 3.5mm, 4.6mm 100mm (Waters, US) col-
umn was used. The column oven was set to 30 C and the injec-
tion volume was 10 ml. The detector was set to 275 nm. Caffeine
elution time was at 4.5min. The total acquisition time was set
to 10min.
Oxantel pamoate samples were prepared by dispersing either
tablet or powder mix or the pure powder in 50ml of N,N-dime-
thylformamid (Carl Roth, Germany). After sonication (approx.
4min), the sample solutions were topped up to 100ml with a
42:58 (v/v) mixture of acetonitrile and formate buffer at pH 2.9.
The 25mM formate buffer was prepared by adding 1.02 g of for-
mic acid (Merck, Germany) to 0.19 g of ammonium formate (Sigma
Aldrich, Germany) in 1 L of water. All the samples were filtered
through a 0.45mm PTFE filter (Wicom, Germany) prior to the ana-
lysis. As a mobile phase, the 25mM formate buffer was used
together with acetonitrile in a binary gradient pump at a flow rate
of 2.5ml min–1. The binary solvent composition was kept at 30%
acetonitrile till 4.00min, followed by a change to 55% acetonitrile
until 5.00min. Between 5.00 and 8.00min, the concentration of
acetonitrile was kept constant at 55%, followed by a change from
55% acetonitrile at 8.00min to 30% acetonitrile at 10.00min. As a
stationary phase the column mBondapakVR C18 10mm 125Å,
4.6m1 50mm (Waters, US) was used. The acquisition time was
set to 10min; the wavelength of the detector was set to 298 nm.
Oxantel pamoate elution time was within 5.5–6.2min.
Dissolution tests
In order to investigate the changes in drug dissolution rate after
stress test without influence of FCC, which is water insoluble min-
eral salt, the dissolution studies were carried out in 1000ml simu-
lated gastric fluid (0.1 N HCl, pH 1.1) for caffeine tablets and in
1000ml of simulated gastric fluid (pH 1.1) with 1% (w/v) of CTAB
for oxantel tablets. For reference purposes the pH neutral media
(distilled water) was used for caffeine formulations and with 1%
(w/v) CTAB for oxantel pamoate tablets. For the experiment the
SOTAX AT7 Smart dissolution apparatus (Sotax, Aesch,
Switzerland) was used. The components of the FCC (calcium
Figure 1. Schematic representation of a manufacturing process for the tablets for
oral suspension.
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carbonate and hydroxyapatite) are soluble in 0.1 N solutions of
HCl, forming solutions of calcium chloride and calcium hydro-
phosphate, therefore, the influence of the insoluble FCC on the
drug particles will be minimized. Paddle speed was set to
100 RPM, samples were collected with piston pump every minute
and analyzed spectrophotometrically (Ultospec 3100 pro,
Amersham Bioscience, UK) in the flow-through 1mm quartz cuv-
ettes at 273 nm and 376 nm for caffeine and oxantel pamoate
samples, respectively. For dissolution trials, the samples before
and after stress test (80 C, 80RH, 7 days) were used.
Scanning electron microscopy
For scanning electron microscopy, the samples were sputtered
with a 20 nm gold layer using Leica EM ACE600 (Germany). The
images were obtained using FEI Nova Nano SEM 230 at the Nano
Imaging Lab (Biozentrum, University of Basel, Switzerland).
Stress test conditions and sample collection
The stress test design follows the 3-factor, 2-level full factorial
design multiplied by trivial single-factor design. As factors for full
factorial design the temperature, humidity, and time were used.
Temperature was varied from room temperature to 80 C (2 lev-
els). The higher level of temperature was chosen to maximize pos-
sible degradation of the model substances within 7 days period.
Under assumption of Arrhenius type of degradation kinetics, the
chosen conditions are comparable to 3months under ICH guide-
lines recommended conditions for accelerated stability test (40 C,
75% RH). Relative humidity (RH) was varied from 5–10% and
73–78%RH (2 levels). Samples were taken after 3 and 7 days,
respectively. The resulting full-factorial design was multiplied by
single-factor (drug type) design, where drug type was varying
between caffeine, oxantel pamoate and placebo. Regression
model used to create the response surface is linear, without quad-
ratic or cubic interactions.
Samples were tested according to schema shown in Figure 2.
A total of 24 runs were investigated for disintegration time in
water and art.sal., hardness and drug content of caffeine and
oxantel pamoate, respectively (see Figure 2). Additionally, the for-
mulations were investigated immediately after preparation (i.e.
under non-stressed conditions) for reference purposes. All meas-
urements were carried out in triplicates.
To obtain the set relative humidity atmospheres, four desicca-
tors were filled with saturated salt solutions: Saturated NaCl
solution was prepared for the 73–78%RH and saturated LiBr solu-
tion was prepared for a relative humidity of 5–10% [21]. To reach
the 80 C an oven Heraeus UT 6200 (Hanau, Germany) was used.
The powder mixtures and pure drug substances were investi-
gated for content only, the placebo tablets were investigated for
disintegration time (water and art.sal.) and hardness as shown in
Figure 2. The verum tablets were investigated for disintegration
time (in water and art.sal.), hardness, and drug content. A regres-
sion analysis was carried out with the software MODDE version
9.0.0.0 (Umetrics AB, Sweden).
The tablets undergoing the stress test showed an average
weight of 498.9 ± 5.5mg. The placebo tablets had a volume of
0.377 ± 0.003 cm3. The tablets containing caffeine had an average
volume of 0.387 ± 0.002 cm3 and the tablets containing oxantel
pamoate had an average volume of 0.415 ± 0.003 cm3.
Results
Formulations prepared according to Table 1 were analyzed to
obtain the disintegration time response surface shown in Figure 3.
The optimum formulation was found at the minimum of disinte-
gration time for all drugs and media. The optimized formulations
are given in Table 1 and marked with an arrow in Figure 3,
respectively.
From the regression analysis, several factors are significant
(p 0.05) for the minimization of disintegration time. For the
response disintegration time in water (goodness of fit: R2¼ 0.90),
the disintegrant concentration and the FCC concentrations are sig-
nificant. Disintegrant concentration has a positive impact, whereas
FCC concentration has a negative influence on disintegration time
in water (i.e. the more disintegrant, the longer the disintegration
time, and the higher the FCC concentration the shorter the disin-
tegration time). For the disintegration time in art.sal. (goodness of
fit: R2¼ 0.9168), the drug influence becomes significant. Oxantel
pamoate has a negative impact on disintegration time, whereas
caffeine increases the disintegration time in art.sal. (i.e. tablets
with oxantel disintegrate faster and tablets containing caffeine dis-
integrate slower).
Stress test results
In Table 2, all the investigated parameters measured immediately
after preparation (i.e. no stress conditions) are shown.
Figure 2. Overview of the conditions, samples, and response variables investigated during the stress test.
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Figure 4 shows the significant factors for the responses (and
goodness of fit, R2) of disintegration time and the constants k1–k3
in water (R2¼ 0.844, 0.851, 0.840, 0.836, respectively) and art.sal.
(R2¼ 0.898, 0.88, 0.918, 0.917, respectively) as well as the hardness
(R2¼ 0.993) and drug content (R2¼ 0.917) of the tablets, powder
mixes (R2¼ 0.845) and pure substances (R2¼ 0.815) after stress
test. Placebo tablets that were stored at 80 C and high humidity
after 3 days for both disintegration time in water and art.sal. were
excluded because they did not disintegrate. Additionally, placebo
and caffeine tablets that were stored at 80 C and high humidity
after 7 days were excluded for disintegration time in water and
art.sal. due to incomplete disintegration.
As shown in Figure 4, the hardness was influenced by several
factors. The significant factors (p< 0.05) were found to be tem-
perature, humidity, and type of drug (i.e. caffeine, oxantel
pamoate, and placebo). The temperature had a positive coefficient
which shows that a higher temperature leads to increased hard-
ness. The influence of humidity is negative, suggesting that the
lower the humidity, the harder are the tablets. For the factor drug
type, caffeine and oxantel pamoate are reversely proportional to
hardness. This shows that the presence of drug leads to lower val-
ues measured for hardness. This is directly supported by the
results of placebo tablets, showing higher hardness values than
verum tablets. The drug containing tablets show higher hardness
values if stored under higher humidity conditions. For the placebo
tablets, high humidity conditions resulted in weaker tablets.
The factors influencing the disintegration rate parameters and,
therefore, the disintegration time in water were: Temperature for
k1, for k2 and k3, temperature as main effect and interaction
between temperature and drug type: caffeine. Disintegration time
Figure 3. The contour plots of the two drugs and the disintegration time in the two test liquids, where (a) shows the disintegration time of caffeine tablets in water,
(b) shows the disintegration time of caffeine tablets in art. sal., (c) shows the disintegration time of oxantel pamoate tablets in water, and (d) shows the disintegration
time of oxantel pamoate tablets in art.sal. The arrow shows the disintegration time of the optimized formulation.
Table 2. Results of disintegration time in water and art.sal., hardness and drug content of the tablets, powder mixtures, and
pure substances prior to stress test (average ± standard deviation).
Parameter Caffeine Oxantel pamoate Placebo
k1 water (s
–1) 0.062 ± 0.254 0.096 ± 0.016 0.118 ± 0.024
k2 water (s
–1) 0.276 ± 0.081 0.472 ± 0.068 0.455 ± 0.153
k3 water (s
–1) 0.256 ± 0.099 0.476 ± 0.07 0.458 ± 0.168
Disintegration time in water (s) 20.2 ± 0.5 18 ± 2 17.1 ± 2
k1 art.sal. (s
–1) 0.089 ± 0.037 0.185 ± 0.044 0.119 ± 0.032
k2 art.sal. (s
–1) 0.363 ± 0.192 0.573 ± 0.151 0.412 ± 0.092
k3 art.sal. (s
–1) 0.362 ± 0.22 0.617 ± 0.175 0.418 ± 0.102
Disintegration time in art.sal. (s) 19.2 ± 1.7 15.1 ± 1.8 18.4 ± 3.4
Hardness (N) 91 ± 2 75 ± 2 96 ± 1
Drug content RDT (%) 99.57 ± 5.11 91.73 ± 8.11 –
Drug content powder mix (%) 102.15 ± 1.19 94.08 ± 8.94 –
Drug content pure substancea (%) 93.32 ± 3.58 98.70 ± 3.79 –
aMeasurements taken for reference purposes.
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in water is influenced by temperature and humidity. All the factors
influencing the sorption and disintegration rate constants had a
negative impact (e.g. the higher the temperature, the smaller the
value for the rate constants). Humidity and temperature had pro-
portional effect on disintegration time (i.e. the higher the humid-
ity and temperature, the longer the disintegration time).
For the rate constants of disintegration time in art.sal., several
factors were significant (see Figure 4). The factors temperature
and caffeine are negatively influencing all the constants as well as
the disintegration time in art.sal. Disintegration time in art.sal. was
influenced significantly by temperature and humidity. The influen-
ces were all negative for k1 (i.e. the higher the factor, the smaller
the constant k1). For k2 and k3, the same is valid.
Drug content of the tablets and the powder mixtures were
only influenced by the type of drug. Content of the pure sub-
stance is not influenced by any factors in a statistically signifi-
cant way.
Dissolution trials
The results of the dissolution experiments are shown in Figure 5
for both model drug substances before and after stress test; as
well as reference release profiles for both model formulations in
water and water/surfactant media. The rate of drug release for caf-
feine samples in SGF did not significantly change after stress test,
both samples release more than 80% (w/w) of the drug within
first 5min for SGF media and <10min for reference water
medium. For the caffeine formulations, the release studies (in SGF)
do not reveal remarkable changes in the release rate after applica-
tion of the stress conditions. However, this is not the case for the
oxantel pamoate formulations. During the dissolution experiments
(in SGF), the formulations after stress conditions were producing
small floating agglomerates, which were present in the dissolution
vessels for a longer time periods compared to unstressed oxantel
pamoate formulations. This behavior can be well reflected by the
release curves, where the rate of drug dissolution of the stressed
tablets is less compared to the reference formulation; however, is
still significantly faster than the latter acquired in water-surfactant
dissolution medium. Both oxantel pamoate samples release more
than 90%(w/w) drug after 15min of dissolution. After the dissol-
ution, experiments were completed (after 25min for caffeine and
120min for oxantel pamoate) the tablets were dissolved com-
pletely, without leaving any visible residuals in the dissol-
ution vessels.
SEM pictures
In Figure 6, SEM pictures of the tablet surfaces are shown for not
stressed as well as after storage under humid and hot conditions.
Before the stress test, the surface of the tablet containing caffeine
was smooth and even. The same is valid for oxantel pamoate tab-
lets. After storage at high RH and higher temperature, the tablets
with caffeine show cracks and ruptures which is not observed for
oxantel pamoate formulation.
Figure 4. Significant factors of the full factorial design for the stress test. In plot (a), the factor influences on the tablets’ rate constants (k1, k2, and k3) measured in
water and art. sal. are shown. An effect of placebo on disintegration rate constant 3 is shown for measurements carried out in art.sal. In plot (b), the influence of
humidity and temperature on the tablet disintegration time in water and art. sal. is shown. Plot (c) shows the influence of temperature, humidity and drug types on
the tablet hardness. In plot (d), the drug content influences on the drug types for tablets and powder mixtures after stability tests are shown. p values are indicated
as error bars; in plots (b–d) the values are too small to be visible. Only significant factors are shown.
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Discussion
It was confirmed that the presence of a disintegrant in the FCC
mixtures are significantly influencing the disintegration time [16].
The increased concentration of AcDiSol leads to slower disintegra-
tion due to its tendency to swell and therefore, at higher concen-
trations, no longer acting as a disintegrant but a hydrophilic
matrix component that prevents liquid penetration. In addition,
the elevated local pH values at the site of croscarmellose sodium
contact points to the FCC particles lead to formation of hydro-
lyzed by-products with increased water solubility, which leads to
swelling front formation [22]. At higher amounts of FCC in a tab-
let, the disintegration time decreases due to liquid uptake
facilitation by porous structure of FCC which is, therefore, essential
for fast disintegration.
There was absence of non-linear effects observed and the
extrapolation performance of the model is sufficient for the for-
mulations optimization task. Therefore, it was possible to validate
the monotonous polynomial model for disintegration time with
the optimal formulation from the central-composite design (see
Figure 3). This is an important side finding for formulations based
on FCC and its derivative products.
The compressive force of 6.8 kN was used to compress the
optimal formulations, which corresponds to compressive stress of
approx. 68MPa. This low compressive stress is resulting in suffi-
ciently high hardness values of 75N, 91N, and 95N for oxantel
Figure 5. Dissolution profiles of caffeine (left, N¼ 6) and oxantel pamoate (right, N¼ 5) tablets, before () and after () stress test (80 C, 80RH, 7 days). The reference
curves obtained from pH neutral media are marked with (w) for caffeine (left) and oxantel pamoate (right) charts. The error bars represent standard deviations.
Figure 6. SEM surface images of caffeine (a and c) and oxantel pamoate (b and d) tablets. Images (a) and (b) correspond to tablet before stress test, the images
(c) and (d) show tablets’ surfaces after stress test under 80 C and high relative humidity.
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pamoate, caffeine and placebo tablets respectively. This confirms
the previous finding made for placebo and paracetamol FCC for-
mulations [15] and now extends to caffeine and oxantel pamoate
model drugs. The values for hardness are in the upper range for a
dispersible dosage form, this allows standard packaging and
ensures tablet integrity during transport.
Before the stress test (time 0), all the tablets showed rapid dis-
integration comparable to the results from optimized formulation.
Caffeine tablets disintegrated by approx. 4 s slower, which is
potentially influenced by lubrication with magnesium stearate.
This addition does not have an impact on the disintegration time
of oxantel pamoate tablets, as this API shares the same hydropho-
bic nature as magnesium stearate.
The tablets that were excluded from the regression analyses
did not show complete disintegration. This result can be explained
by drug recrystallisation or irreversible swelling of the disintegrant
under higher humidity. In the latter case, the disintegration cap-
acity of croscarmellose sodium was no longer sufficient to ensure
complete disintegration. This effect of reduced performance of
AcDiSol is already known in the literature in context of wet-granu-
lation [23]. The tablets containing oxantel pamoate did disinte-
grate completely which suggests that the hydrophobic nature of
the drug, distributed around the granules shielded them from this
effect. Apparently, this effect is stronger in the inner part of the
tablets, leading to partial tablet disintegration with solid non-
disintegrating core.
The sorption rate constant k1 is inversely proportional to tem-
peratures, suggesting slower liquid sorption resultant of storage at
higher temperature. Under elevated storage temperatures, the
FCC particles are consolidating, making interparticulate voids
tighter. This leads to a slight inhibition of the water uptake by the
tablets. This tightening was also shown by the increase of hard-
ness at increasing temperatures. The higher the humidity and
temperature, the slower the tablets were disintegrating. The same
is valid for disintegration time in art.sal. Moreover, the drug type
caffeine influences all three constants of disintegration in art.sal.
The hardness was shown to be significantly influenced by tem-
perature, humidity and presence of drug. High storage tempera-
tures lead to harder tablets, whereas humidity leads to softer
tablets. This can be explained by the behavior of AcDiSol in the
formulation. Under heat, the tablets are temperature cured, which
leads to strong bonds between the granules due to drug recrystal-
lisation, especially for drugs with tendency to sublimation-recrys-
tallization, such as caffeine. Humidity, on the other hand, leads to
pre-swelling of AcDiSol, which reduces tablet stability. The pres-
ence of drug as well as any other substances reduces tablet hard-
ness; as the FCC granules alone have a higher surface available for
interlocking compared to the tablets containing drug, any admix-
ture which reduces the contact surface of the FCC particles will
depress the mechanical stability of the compacts. The SEM pic-
tures revealed that the recrystallizing of the caffeine under high
temperatures led to the formation of cracks, which causes the caf-
feine tablets to be weaker than the oxantel pamaote and placebo
formulations. After the stress test, the drug content did not
change, which is indicating that there was no degradation of API
in presence of FCC.
The results of the dissolution test show a certain impact of
stress conditions (80 C and 80%RH) on the release pattern of the
model drug substances. This impact is negligible for caffeine tab-
lets, however can be seen as release rate reduction for oxantel
pamoate tablets. One of the possible explanations for this effect is
a secondary agglomeration, i.e. curing, of drug particles into larger
aggregates which dissolve slower as primary drug crystalls. This is
supported by the visual observations during the dissolution tests,
where the floating particles were seen for a longer time for
stressed samples. In general, the changes to the release profiles of
the tested FCC-based formulations can be considered as minimal,
the 80% release of both drugs before and after stress conditions
happens within first 20min of dissolution, which is can be classi-
fied as fast, unmodified release formulation. Although, the com-
parative results were obtained from acidic media, where the
influence of undissolved calcium carbonate and calcium phos-
phate on the drug particles dissolution is minimized, the reference
profiles obtained in water and water-surfactant media allow to
assume a similar tendency for dissolutions in pH-neutral buffers.
The significant reduction in dissolution rates for both model sub-
stances observed in the reference profiles is explained by partial
obscuration of a solid-liquid interface of drug crystals by insoluble
and inert FCC. This is well supported by a high specific surface
area of the FCC particles, reaching up 60m2 g–1. The effect of
release rate inhibition due to geometric features of the filler
material is very well seen for oxantel pamoate formulations
(Figure 5, right), where untreated tablets dissolve completely in
acidic buffer within 5min, whereas the same tablets tested in pH
neutral medium show significantly slower release pattern.
Conclusion
It can be concluded that the two model drugs in the studied FCC-
based tablets for oral suspension do not show any chemical
degradation. The content was not influenced by humidity, tem-
perature nor storage time. Humidity and temperature did influ-
ence dissolution rate, disintegration, and hardness of the tablets.
We can conclude that the FCC-based formulation platform can be
used to manufacture physically stable, fast disintegrating, unmodi-
fied release tablets when stored at the normal conditions (i.e.
room temperature, dry condition). The formulations can withstand
the stress conditions keeping the drug substances stable for
longer periods of time.
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Study of Drug Particle Distributions within Direct-Compressible 
Mini-tablets Using Synchrotron X-ray Microtomography and 
Superpixel Image Clustering 
 
 
Abstract 
Drug distribution in fast disintegrating tablets is of high importance, especially when used to treat 
local infections in the gastrointestinal tract, such as helminths. In this work, the drug particle 
distribution in mini-tablets was studied with synchrotron phase contrast X-ray microtomography, 
using a simple linear iterative clustering (SLIC) superpixel method for segmentation analysis. The 
compositional results from the X-ray microtomography were compared to and found to be in good 
agreement with chromatographic measurements. The presented method can be used for the 
quantitative analysis of drug content and drug distribution within pharmaceutical tablets and for 
optimization of fast disintegrating formulations, such as those used for local treatment of parasitic 
infections. The results of the content uniformity analysis suggest the safe concentration region to 
prepare direct-compressible robust formulations for anti-infective drugs, such as moxidectin. 
 
Keywords: synchrotron X-ray microtomography, functionalized calcium carbonate, moxidectin, 
distribution analysis, superpixel clustering, percolation theory.  
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Introduction 
According to major pharmacopoeias, the drug content uniformity (CU) is one of the major quality 
attributes associated with medicinal products. In case of solid preparations such as tablets and 
capsules, the CU is a measure of a dose distribution within a limited-size sample set, i.e. 10-20 tablets 
or capsules. However, the CU, as a formulation characteristic, is not providing any information about 
spatial distribution of a drug substance within an individual dosage form (1). Such information is of 
high importance for fast dispersible delivery platforms, such as orally disintegrating or rapidly 
disintegrating tablets. The therapeutic advantage of such formulations is due to efficient and fast 
distribution of the drug particles near the site of action, e.g., for local treatment of gastro-intestinal 
infections (2). Failure to evenly distribute the drug in a single tablet leads to formations of drug 
agglomerates and therefore poor therapeutic outcomes despite a good dose distribution between tablets 
from the same batch. 
The tablet formulations for local treatment in the gastrointestinal tract (GIT), specifically anthelmintic 
therapies, require methods to assess the drug particle spatial distribution in an individual dosage unit. 
This is especially important for anthelmintic low-dose moxidectin preparations, for example. 
Moxidectin is an anti-parasitic drug used in the veterinary field (3,4), mostly for livestock treatment, 
such as sheep (3), horse (4) or goat (5). In the last few years, moxidectin has been used in humans in 
clinical trials carried out in Côte d’Ivoire and Tanzania, in order to investigate its anthelmintic 
therapeutic efficacy (6,7). The mode of action of moxidectin bases on the selective paralyzing of the 
parasite by increasing muscle Cl- permeability (8). Moxidectin shares this mode of action with the 
other avermectins (ivermectin, abamectin, doramectin and milbemycin D). To guarantee an effective 
local action in the intestinal tract, the drug needs to be precisely dosed and the dosage form must allow 
high dispersibility. The required dose regimens are comprising 8mg (6,7), which is relatively low 
considering the average bodyweight of 39.4 kg in the study with adolescents and 54 kg for adults, 
respectively (6,7). The yielding dose is therefore between 0.15 mg and 0.2 mg per kilogram of 
bodyweight. A dosage form is required to provide accurate dosing with excellent drug dispersibility in 
the intestinal lumen and good patient compliance. Helminth infections are mostly prevalent in low and 
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middle income countries (9,10), therefore it is important to avoid high production-cost formulations, 
maintaining high quality standards (11). 
To fulfill the aforementioned requirements, the low dose fast dispersible small size or mini-tablets 
produced by direct compaction can be a strategy of choice. Mini-tablets (size of 2-3mm) are a solid 
dosage form that is accepted by trained children between the age of 6 months and 6 years (12). 
Functionalized Calcium Carbonate (FCC) based fast disintegrating formulations were previously 
investigated in palatability studies, reporting excellent compliance benchmarks (13). A rapidly 
disintegrating version of a mini-tablet – orally disintegrating mini-tablets (ODMT) – are proposed to 
be even more convenient for the use in the pediatric population (14). In general, ODMTs have good 
compliance in all age groups (15), are not difficult to swallow (16) and, if rapid disintegration is 
provided, can allow the intake without water (17). The dose can be quantized per mini-tablet and can 
be easily adjusted according to specific needs by varying the number of mini-tablets administered 
(18). Moreover, if the mini-tablets are made with FCC-based fast disintegrating granules, an optimal 
local treatment in the intestinal lumen can be expected (2). On the other hand, the agile disintegration 
of the FCC-based granules does not guarantee a uniform drug distribution in the lumen of GIT due to 
possible agglomerates formation during blending and tableting processes. Therefore, it is necessary to 
investigate and understand the distribution of a drug within such tablets. In the current study, mini-
tablets composed of moxidectin and functionalized calcium carbonate (FCC) were used as model drug 
delivery systems to study the drug particle distribution with X-ray microtomography as a function of 
drug load. 
X-ray microtomography is an established non-destructive technique used in research fields as diverse 
as paleontology, materials science, biomedical research, earth sciences and in many others, as well as 
in industrial R&D and quality assurance processes, capable of determining the internal three-
dimensional structure of samples with submicron resolution. In contrast to laboratory-based computed 
tomography systems running on X-ray tubes, the high brilliance and nearly parallel beams provided by 
synchrotron beamlines allow for a higher resolution and much faster scans, while the partially 
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coherent beams enable the use of phase information to boost the contrast between materials with very 
similar X-ray absorption coefficients and atomic densities, such as many organic materials (19). 
The aim of this work is to measure the 3D spatially resolved drug particles’ and clusters’ positions in 
mini-tablets and to quantitatively determine the corresponding drug distribution. We apply 
synchrotron X-ray microtomography with phase retrieval filtering to obtain the volumetric scans of the 
tablets with high phase specificity of the constituting ingredients. The SLIC superpixel clustering 
analysis is used to generate discrete scalar fields of tablet components from gray-scale values. The 
conventional method (i.e. chromatography) to determine the content uniformity of the tablets was 
compared to the results from the tomographic investigations.  
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Material and Methods 
Production of rapidly disintegrating granulate and mini-tablets 
The granulate used to produce the mini-tablets was manufactured by roller compaction followed by a 
milling step. The granulate described in this publication is equal to the Omyapharm FCC granulate 
used in another work by Wagner-Hattler et al. (13). It contains 97% Omyapharm FCC (Omya 
International AG, Switzerland) and 3% crosscarmelose- sodium (AcDiSol FMC, US). 
Four different formulations were prepared. First, the Omyapharm FCC granules fraction 180-710 µm 
and moxidectin USP37 (Livzon New North River Pharmaceutical Co, Ltd., China), sieved <500 µm 
were blended in a Turbula powder blender T2C (W.A. Bachofen, Switzerland) for 10 min at 34 rpm. 
To avoid sticking of the compacted mini-tablets to the punches and die walls, the granules were 
blended with 2% (w/w) magnesium stearate for lubrication. The compositions of the formulations are 
shown in Table I. 
Table I: Composition of the four formulations and their nomenclature 
Nomenclature Moxidectin (%, w/w)  Granule (%, w/w) 
DL 2.5 2.5 95.5 
DL 5.0 5 93 
DL 9.0 8.88 89.12 
DL 20.0 20 78 
All formulations contained 2% (w/w) magnesium stearate, sieved <500 µm. 
The mini-tablets from four formulations (Table 1) were produced with a Styl’One Classic compaction 
simulator (Medel’Pharm, France), equipped with 12 mini punches of 2 mm diameter and a cap 
curvature radius of 1.4 mm (Notter, Germany). The mini-tablets were compacted with 80 MPa 
compressive pressure. The filling height was adjusted to obtain a tablet weight of approximately 10 
mg (weighed with Kern balance ABT 120-5DM, Kern+Sohn GmbH, Germany). After compaction, the 
diameter and height of 10 individual mini-tablets were measured with a digital caliper. All tablets had 
a height of 2.74±0.1 mm and a diameter of 2.01±0.01 mm. 
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X-ray microtomography 
Synchrotron X-ray microtomography measurements of the tablets were performed at the TOMCAT 
X02DA beamline of the Swiss Light Source at the Paul Scherrer Institute (Villigen, Switzerland) (20). 
The X-ray beam produced by the superconducting bending magnet source was monochromatized to a 
beam energy of 19.9 keV using a large bandwidth (E/E ~ 2%) Ru/C multilayer monochromator. 
Samples were placed in the essentially parallel X-ray beam about 25 meters from the source. The 
radiographic projections of the sample were converted to visible light by a 20 µm thick LuAG:Ce 
scintillator coupled to an optical light microscope with a 10-fold magnification (Optique Peter, 
France), placed 12 mm downstream of the sample to obtain some degree of edge enhancement for 
phase contrast reconstructions. The magnified image was recorded using a pco.Edge 5.5 sCMOS 
camera with 2560 x 2160 pixels (h x v) of 6.5 µm in size, resulting in an effective pixel size of 0.65 
µm and a field of view (FOV) of 1.66 mm x 1.40 mm (h x v). 
In order to fit the entire tablet diameter into the reconstructed volume from one scan at this resolution, 
we used an extended FOV scanning protocol, rotating the sample through 360 degrees while placing 
the rotation axis near one side of the detector frame (21). This results in almost a doubling of the 
horizontal FOV (a small bit of projection overlap is required). A total of 3601 projections with an 
exposure time of 250 ms were recorded per scan, resulting in a scan time of approximately 15 minutes. 
In the vertical direction, it was necessary to acquire two slightly overlapping stacked scans to fit the 
total height of the tablet. Hence, the total measurement time per tablet was around 30 minutes, and the 
overall FOV covered about 3.31 mm x 2.78 mm (h x v). 
Tomographic reconstructions were computed after applying a single distance propagation-based phase 
contrast filter (22), using a / ratio of 50, with the gridrec reconstruction algorithm employing a 
standard ramp filter (23).This resulted in a sufficiently strong contrast between the Omyapharm FCC 
and moxidectin phases. The volume data was cropped down to 3701 x 3701 pixels in the axial cutting 
plane during the reconstruction since this was sufficient to fit the entire tablet diameter, thus limiting 
the horizontal extent of the reconstruction to about 2.4 mm. 
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Data analysis 
The analysis of the reconstructed data was performed in Image J 1.51j8 (National Institutes of Health, 
USA) by first binning by factor 4 in all dimensions using an averaging function to reduce the memory 
footprint necessary for effective computation, followed by a SLIC clustering analysis for the 
segmentation of mini-tablet components (24). To increase the discriminative efficiency of the 
segmentation algorithm, a circular mask was applied to the reconstructed images to discard the air 
volume around the tablet. After clustering, the volumetric percentage of each component was 
calculated as the ratio between the number of voxels assigned to each phase and the total number of 
voxels in the tablet, including pores. To obtain the mass of the component from the microtomography 
scans, the number of voxels corresponding to that component was multiplied by its density. Since all 
mini-tablets have a bi-convex geometry, the analysis was carried out for the cylindrical part of the 
tablet only to ensure accurate clustering results. Clustering and analysis were performed separately on 
both vertically stacked scan volumes and the final metrics were calculated as the average of those two 
data sets. The result of the clustering algorithm is a three-dimensional array of byte-sized scalars, 
which is referred to a voxel of 0.275 µm3 in volume. Each of the voxels was assigned to a type 
corresponding to a cluster intensity. 
The resulting number of components found by the segmentation algorithm was variable, however 
mostly yielding three main components of the studied formulations. The first component is the drug 
moxidectin, the second component is the FCC granules and third component has been classified as a 
mix of moxidectin and FCC intensities. Porosity was not detected by the clustering algorithm, neither 
cracks nor other types of air pockets. The apparent true density of moxidectin used to convert between 
volumetric and mass percentages was 1.23 g/cm3.  
The final drug content calculations from clustered microtomographic images have been corrected for 
sodium croscarmellose content in those cases where the X-ray absorption coefficients of drug particles 
and croscarmellose fibers were indistinguishable for the SLIC clustering algorithm. Furthermore, due 
to a very low contrast to other formulation components, the 2% (w/w) of the magnesium stearate 
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phase could not be reliably detected by the SLIC algorithm; and thus, are not separately assessed in 
this study. 
To obtain the density of the compacted FCC-granule, the weight of a mini-tablet containing no drug 
was divided by the volume of the same tablet. The volume was calculated according to equation 1. 
𝑉 = 2 ∙ (
𝜋
3
 ∙ ℎ𝑐
2 ∙ (3𝑟𝑐 − ℎ𝑐)) + 𝑟𝑡
2 ∙ 𝜋 ∙ ℎ   eq.1 
Where V is the volume of the tablet in cm3, hc is the height of the cap, rc is the curvature radius of the 
cap, rt it the radius of the tablet, and h is the height of the cylindrical part of the tablet, i.e., 2∙hc 
subtracted from the total height of the tablet. The value hc was calculated by subtracting √𝑟𝑐
2 − 𝑟2 
from rc. All lengths are measured in units of centimeters. 
To obtain a measure for the spatial drug distribution, the three-dimensional images of reconstructed 
tablets were subdivided into several equal volume cylindrical annular regions. The start and end radii 
of the annuli were calculated as follows:  𝑟(𝑖, 𝑛)𝑠𝑡𝑎𝑟𝑡 = √
𝑖
𝑛
𝑟𝑡
2, and 𝑟(𝑖, 𝑛)𝑒𝑛𝑑 = √
𝑖+1
𝑛
𝑟𝑡
2, where i is 
the index of an annulus from the total number of annuli n. The radius rt is the tablet radius. For each 
annulus the sum of voxels associated with drug substance was calculated. The low annulus numbers 
are corresponding to the volumetric regions at the center of the tablet and higher numbers are towards 
the tablet walls. Total number of subdivisions n has been set to 30. In Figure 1 an example distribution 
histogram is shown for a uniform drug particle distribution in the cylindrical part of the tablet. 
Calculations were made with Wolfram Mathematica 11.0 (Wolfram Research, Inc., Version 11.0, 
Champaign, IL, USA). 
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Figure 1. An example histogram of a uniform drug voxels distribution in a cylindrical volume 
subdivided by 30 equally-sized annular volumes. On the abscissa to the distances of the annulus 
from tablet center are given. 
Chromatographic Analysis of Drug Content 
The tablet content was analyzed using a Shimadzu Nexera 2 UPLC System. To detect moxidectin, the 
Ph.Eur. method for moxidectin was applied (25). The tablet was dissolved in 5 ml acetonitrile (Carl 
Roth, Germany) and crushed with a glass rod. After 10 min of sonication, the suspension was filtered 
using a 0.45 µm PTFE filter. For UPLC analysis, a mobile phase of 40% (v/v) ammonium acetate 
buffer 0.25M and 60% acetonitrile (v/v) at a flow rate of 2.5 ml/min was used. The ammonium acetate 
buffer contained 7.7 g ammonium acetate (Carl Roth, Germany) in 400 ml of water. The pH was 
adjusted to 4.8 with glacial acetic acid (Hänseler AG, Switzerland). For chromatographic separation 
(15 min acquisition time, in triplicates), a column ResolveTM C18, 5 µm, 90 Å, with a diameter of 3.9 
mm and a length of 150 mm was used (Waters, USA), the column temperature was set to 50ºC, the 
detector wavelength was set to 242 nm, and the injection volume was 10µl. 
57 
 
Results 
The production of mini-tablets from the powder blends according to Table 1 did not reveal any 
complications, i.e., there were no signs of capping, lamination, picking or sticking behavior. The 
tablets were stable and uniform in weight and geometrical dimensions. The results of the measured 
parameters of the mini-tablets such as the weight (N=10) and effective dose (N=10) are shown in 
Table II. The measured contents of the individual mini-tablets were scattered in a fairly wide range 
(i.e. >20% for DL2.5), except for DL9.0, which showed a considerably lower variation of about 5% 
RSD. 
Table II: Target dose, measured content and the acceptance value of the four formulations 
Formulation Tablet 
weight (mg) 
Target dose 
(mg/tablet) 
Effective dose 
(mg/tablet)±CI 
(95%) 
Effective dose to 
target dose ratio 
(%)±SD 
% RSD 
DL 2.5 9.87±0.34 0.25 0.3±0.03 121.38±20.65 17.01 
DL 5.0 9.72±0.51 0.49 0.44±0.05 90.88±16.71 18.39 
DL 9.0 9.39±0.37 0.83 0.89±0.03 106.22±5.19 4.89 
DL 20.0 9.71±0.55 1.94 2.12±0.15 109.21±12.32 11.28 
 
The measured content in percent of the target dose ranged from 93.2% -152.0% for DL2.5, from 
62.8% -122.1% for DL5.0, from 93.9%-112.9% for DL9.0 and from 86.8%-128.5% for DL20.0. 
 
As shown in Figure 2, it is possible to visually differentiate the four main formulation components in 
the reconstructed image, i.e., drug, calcium carbonate/hydroxyapatite granules (FCC), croscarmellose-
sodium, and air. The FCC material appears in light gray values due to its higher absorption of the x-
ray photons. The dense crystals of calcium carbonate appear as almost white spots on the FCC 
material. Drug substance and the croscarmellose appear in similar grey levels due to similar qualitative 
chemical compositions. A qualitative distinction between these two materials is only possible by shape 
and location of the croscarmellose fibers entrapped in the FCC granules. 
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Figure 2: The six different components of the formulations visually differentiated for a non-clustered 
image: a) moxidectin, b) croscarmellose-sodium, c) dense calcium carbonate crystals surrounded by 
calcium phosphate (light gray), d) compressed FCC particles, e) pores, f) mixture material of moxidectin 
and FCC 
Inspecting the second magnification in Figure 2 (upper right corner) closely, the different intensities 
for calcium carbonate and calcium phosphate are evident. In some parts of Figure 2, the edges of the 
single grains are visible as well. The single granules look intact and do not show any cracks or 
disruptions. The same can even be seen at the edges of the tablets, where the FCC granules were in 
direct contact to the die walls during compression. Visual inspection of the reconstructed mini-tablet 
images did not show a significant number of air pockets, there were no laminations nor cracks 
detected. The tablets look non-porous, the porosity of the tablets is solely associated with the porosity 
of the FCC granules, and constitutes of ~40% (v/v) (26). Particular attention should be payed to the 
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mixture material, which appears as an intermediate gray between FCC and moxidectin. The mixture 
material (MM) is mostly located at the contact surface between drug and FCC granules. 
The reconstruction results with simple absorption contrast did not produce sufficient differentiation for 
the cluster analysis between formulation components. An application of the Paganin phase retrieval 
filter was necessary to obtain a sufficient contrast to allow for a reliable segmentation. The cluster 
analysis was therefore only carried out for phase contrast reconstruction images (see Figure 3). 
 
Figure 3: A cross-sectional axial slice through the phase contrast reconstructed volume data set of a mini-
tablet (left) together with the corresponding results of the SLIC clustering (right). The clustering 
algorithm allows a reliable and discriminative breakdown of gray scale values to differentiate the three 
main tablet components: FCC (white), Moxidectin (red), and Croscarmellose Sodium and mixture 
material (MM) (blue).  
 
The clustering algorithm recognizes this mixture material (MM) on all cross-sections for all 
formulations. On the right side of Figure 3 and in Figure 2, this mixture material structure can be seen 
in blue or light gray, respectively. It consists of lamellar calcium phosphate, denser crystals of calcium 
carbonate and drug, which leads to averaged X-ray opacity. The quantitative composition of the 
mixture material cannot be obtained from these images. 
60 
 
The reconstructed grey level values of the fibrous component (i.e. croscarmellose-sodium) were not 
sufficiently different to discriminate them from the mixture material; therefore, the clustering 
algorithm recognizes these fibrous structures as mixture material and drug. Nevertheless, the 
distribution of the fibrous component in the FCC granules can be visually inspected. 
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Table III: Results of the SLIC-clustering analysis of moxidectin content in the four formulations (n=2)  
 
Drug Concentration, %, 
w/w 
Percentage of the 
expected dose, 
%, w/w 
Average percentage of 
the dose for the whole 
cylindrical part of a 
tablet, %, w/w 
DL2.5, tablet 1, lower part 3.2 128.4 176.3 
DL2.5, tablet 1, upper part 5.6 224.2 
 
DL2.5, tablet 2, lower part 1.6 63.0 72.0 
DL2.5, tablet 2, upper part 2.0 81.0 
 
DL5.0, tablet 1, lower part 5.8 116.1 116.3 
DL5.0, tablet 1, upper part 5.8 116.5 
 
DL5.0, tablet 2, lower part 5.4 108.5 112.3 
DL5.0, tablet 2, upper part 5.8 116.2 
 
DL9.0, tablet 1, lower part 8.7 96.8 98.5 
DL9.0, tablet 1, upper part 9.0 100.1 
 
DL9.0, tablet 2, lower part 8.8 97.7 98.4 
DL9.0, tablet 2, upper part 8.9 99.2 
 
DL20.0, tablet 1, lower part 21.9 109.6 122.5 
DL20.0, tablet 1, upper part 27.1 135.5 
 
DL20.0, tablet 2, lower part 23.6 118.0 158.3 
DL20.0, tablet 2, upper part 39.7 198.5 
 
 
In Figure 4, the composition analysis results from the clustering analysis as shown in Table III are 
compared to the drug content in mini-tablets obtained from liquid chromatography measurements 
(Table II). Only the results of drug content determination from the clustering analysis for formulation 
DL9.0 are close to the expected range. With an increased number of microtomographic measurements 
per formulation, the accuracy and precision of this quantification method is expected to improve. As  
an additional factor contributing to the deviation between expected and obtained drug concentration 
from image analysis, is the mixture material with unknown composition. The segmentation algorithm 
has been applied on the binned (factor 4) images, thus introducing 64-fold averaging. This and an 
exclusion of the minitablets’ cups regions from the analysis leads to an introduction of additional error 
to the results. 
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Figure 4: Correlation plot of average moxidectin concentration measured with chromatographic method 
vs. calculated from microtomography data.  
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Figure 5: Results of the clustering analysis. In the left column, the phase contrast reconstructed and 
clustered volume data is shown for all four tablet formulations; The middle and right columns show the 
three-dimensional rendering of the volume comprised of only the drug and FCC component, respectively. 
All other phases are not visible as they have been made fully transparent in the rendering. 
In Figure 5, the middle and right columns show a rendering of the drug and FCC volume surfaces 
extracted from the reconstructed and clustered images in three dimensions. To statistically analyze the 
drug component distributions within different formulations, the results of the drug voxels occurrences 
versus distance to the tablet center are shown in Figure 6. A uniform distribution (Figure 1) of the drug 
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particles in a tablet results in equal values for all annual volumes. As shown in Figure 6, the studied 
formulations do not feature an ideal uniform distribution of the drug within a tablet. The effect of drug 
material migration from the tablet center towards tablet walls is increasing with increased drug load.  
 
Figure 6: Histograms of the of the drug particle distribution with respect to radial position in the tablet 
for the four different formulations DL 2.5, DL5.0, DL9.0, DL20.0. Standard deviations are shown as error 
bars. 
  
65 
 
Discussion 
Among all the tested tablets, the DL9.0 formulation shows the best content uniformity measured by 
liquid chromatography. This finding is consistent with the microtomography results, although, due to 
the small number of samples measured with tomography, the latter result is lacking statistical 
relevance. The deviation of content between microtomography and chromatography results for DL2.5 
and DL5.0 formulations is significantly less than the deviation found for DL20.0 tablets as seen in 
Figure 4. Interestingly, this finding supports the concept of the percolation theory (27), which is 
stating the presence of a fixed critical concentration, i.e. a percolation threshold, in the vicinity of 16 
% (v/v) (28). If the effective drug load is expressed in the volumetric concentrations, assuming the 
moxidectin apparent crystalline density equal to 1.23 cm3/g, the resulting percentages are 3.3%, 4.8%, 
9.8% and 23.3% for DL2.5, DL5.0, DL9.0 and DL20.0, respectively. This shows that the critical value 
of 16% (v/v) must be located between DL9.0 and DL20.0 formulations. It means that all formulations 
with moxidectin content below 16% are qualitatively different to DL20.0. In this respect, the 
formulations with drug content greater than the percolation threshold show stronger drug cohesion 
interaction rather than drug-FCC interaction during powder blending, thus inducing segregation and 
therefore higher deviation in the content.  
The results of the distribution analysis reveal that the drug particles are fairly uniformly distributed for 
all studied formulations, with slight increase in drug content towards the outer rim of the tablets. The 
effect of the drug substance accumulation near the tablet walls is slightly higher with increase in drug 
load. It can be hypothesized that this nonuniformity in distribution is induced by a preferential radial 
migration of the drug particles during compressive deformation (29,30). However, this effect is not 
strongly pronounced. Based on (29), this migration of the material to the die walls during tablet 
compaction is not surprising, however, this effect can be expected for lubricant components only, such 
as magnesium stearate.  Nevertheless, the observed difference in the drug distribution for 20% drug 
loading does not directly explain the deviation in the content. As it is seen in Figure 5, the FCC 
granules are no longer forming a spanning cluster throughout the tablet geometry, in contrast to the 
moxidectin component. The FCC granules are almost suspended and isolated from each other in the 
percolating drug. Therefore, the higher amounts of the drug induce a secondary agglomeration of the 
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drug particles as the net cohesive forces dominate the adhesion of the drug to the FCC surfaces. This 
finding corroborates the hypothesis suggesting an increased risk of segregation during powder 
blending and also content uniformity issues. The presence of the secondary agglomeration also 
suggests a potential reduction in drug dispersibility in the gastro-intestinal tract after administration. 
Non-uniform distribution and lumps appearance should be avoided in the formulation of drugs for 
local treatment, such as anthelmintic preparations.  
The important outcome of the visual and the correlation analysis suggest that fast disintegrating FCC 
granules are suitable for low (i.e., below 15% w/w) drug load (i.e., below percolation threshold 
concentrations) direct compression formulation development, which therefore allows for significant 
simplification of the medicine production process.  
Another important result from the visual analysis is that the granules remain integral during tablet 
compaction, i.e., granular crushing does not take place, even at those sites where such destructive 
deformation is normally expected, for example in close proximity to the die walls. This effect can only 
be explained by the properties of the FCC-based granules used as bulking and fast-disintegrating 
component. FCC particles are featuring a significantly high specific surface area (approx. 70 m2/g), 
due to developed lamellar structures on the surface of the individual FCC particles. These lamellae 
interlock under mild compressive stress, allowing for strong Van der Waals interactions due to high 
contact surface, which leads to formation of hard yet very porous compacts. However, at the interfaces 
between drug and FCC granules such interaction is less evident; therefore, the formation of a mixture 
material can be clearly seen on the microtomographic images. The nature and origin of this material is 
not clearly revealed by the data. The specific features of FCC particles, i.e. denser carbonate cores, can 
be detected in the mixed layers, and we can assume that the drug particles are present in this mixture 
as well. Whether this material was formed by attrition and detachment of the individual FCC particles 
during the blending process or in situ during compaction requires further investigation; however, the 
appearance of this mixture may support a hypothesis that the rough granular surfaces may assist 
uniform drug layering during powder blending. Further investigation of this phenomenon may suggest 
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different recommendations of the blending times during powder mixing than those which are 
conventionally recommended. 
 The results of this work have shown that the Paganin filters for material information retrieval during 
the tomographic reconstruction of the pharmaceutical formulations is an enabling step to quantities 
analysis of pharmaceutical tablet formulations. The combination of this method with segmentation 
algorithms allows quantitative and special analyses of the drug distribution in the tablets.  
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Conclusion 
We have successfully applied a combined method to investigate and quantify the moxidectin drug 
particle distribution in mini-tablet formulations with Omyapharm FCC as a main excipient. 
The proposed combined analysis of the content and drug particles distributions confirms the 
applicability of the direct compaction method to produce tablets with required content uniformity and 
fast dispersibility of the drug in the human GI tract. The identified issue with content uniformity for 
drug loads greater than 9% can be explained with the concept of a critical concentration for three-
dimensional geometries with randomly distributed components. The concentrations below 16% (v/v) 
can be considered as low risk with respect to segregation. As suggested from the percolation theory 
the formulations in the direct vicinity to the percolation threshold are prone to stochastic behavior; 
thus, the robust direct-compressible formulations with Omyapharm FCC granules can be achieved at 
drug concentrations less or equal to10% (v/v). 
The investigated formulations with 2.5-9% (w/w) drug load can serve as a starting point for 
formulating low-dose anthelmintic formulations with moxidectin, or other avermectins, where low 
dose and fast and effective drug distribution is required. 
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ABSTRACT
A new mineral–polymer composite (FCC-PCL) performance was assessed to produce complex geometries
to aid in development of controlled release tablet formulations. The mechanical characteristics of a devel-
oped material such as compactibility, compressibility and elastoplastic deformation were measured. The
results and comparative analysis versus other common excipients suggest efficient formation of a complex,
stable and impermeable geometries for constrained drug release modifications under compression. The
performance of the proposed composite material has been tested by compacting it into a geometrically
altered tablet (Tablet-In-Cup, TIC) and the drug release was compared to commercially available product.
The TIC device exhibited a uniform surface, showed high physical stability, and showed absence of friabil-
ity. FCC-PCL composite had good binding properties and good compactibility. It was possible to reveal an
enhanced plasticity characteristic of a new material which was not present in the individual components.
The presented FCC-PCL composite mixture has the potential to become a successful tool to formulate con-
trolled-release dosage solid forms.
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Introduction
Controlled release dosage forms present a possibility to prolong
drug release over several hours [1,2]. Considerable techniques,
such as hydroxypropylmethylcellulose (HPMC) [3] or hydroxypro-
pylcellulose (HPC) [4] in a matrix and using semipermeable mem-
branes in osmotic-controlled release oral delivery system (OROS)
[5,6] are known. Well established methods to control the drug
release, e.g. hydrophilic HPMC matrix, often result in low drug
loads due to a higher demand of a matrix components in a formu-
lation. Therefore, a geometric alteration, such as a release surface
constraint, is appealing to employ in combination with release sus-
taining excipients. To control the drug-release profile by geometric
alteration there are number of successful examples. GeomatrixVR
[7], Smartrix [8], donut-shaped tablets [9], one-step dry-coated tab-
lets (OSDRC) [10] or Dome MatrixVR [11] are controlled-release
products which take advantage of this approach. Release-rate
modification by geometric alteration is desirable, however, difficult
due to lack of suitable materials. Physical stability, compactibility
[12], manufacturing [13], scale-up [13] and risk of dose dumping
[14] are known issues associated with these formulations. Because
individual materials suitable for pharmaceutical manufacturing lack
these mentioned properties, polymer-mineral composites are of
particular interest. Functionalized calcium carbonate (FCC) has
already shown good performance to enhance disintegration, com-
pressibility and compactibility while being admixed with other
excipients [15–17]. FCC is easily compactable and has particles
with an array of randomly oriented lamellae that form a porous
meshwork. FCC tablets yield high tensile strength at low
compressive pressures [16]. Calcium carbonate is in general inert
to a large majority of active substances [18,19]. The second com-
ponent of FCC, calcium phosphate, is as well commonly used as a
diluent for capsules and tablets [19].
Production of a polymer-mineral mixtures through a hot-melt
extrusion process is a common practice in material engineering to
produce structure with improved mechanical properties [20–22].
For industrial pharmacy, a hot-melt extrusion process is of
interest for product quality enhancement (i.e. less process variabil-
ity [23] and easy scale up by time extension [24]) during large-
scale manufacturing.
To summarize all above mentioned, it is important to identify
and test material for industrial manufacturing of more complex geo-
metries than a simple tablet. There were a number of projects pre-
sented in the past to facilitate the accomplishment of similar task
[7,8,25]. While many of those materials intent to solve individual
problems, almost none are covering the entire required spectrum.
The aim of the current study is to characterize the FCC-PCL
composite material for its physical stability, mechanical properties
under compressive deformation, and its suitability for geometry-
constrained sustained release formulation development.
For better scale-up it is quite important for a material of choice
to exhibit high flowability under compressive stress to be able to
fill the gaps or voids of a complex geometry.
The success is in combining different methods i.e. geometric
alteration, low excipients concentration and ease in production.
The novel tablet-in-cup (TIC) device is presented as an example
tool to formulate efficiently controlled release dosage forms with
the new composite material to improve the patient compliance,
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especially in children or patients with swallowing problems by
reducing the volume of a final tablet. The TIC performance was
compared to that of the marketed product KombiglyzeVR XR.
Materials and methods
The core tablet consisted of 96% (m/m) metformin HCl (Harman
Finochem Limited, Mumbai, India), 2% (m/m) polyvinyl alcohol
(PVA) (Nippon Goshei, Osaka, Japan), and 2% (m/m) Carbopol 980
NF (Lubrizol, Advanced Materials, Brussels, Belgium). The FCC-PCL
composite consists of a 1:1 (m/m) mix of Omyapharm FCC (VP-
220976 S03) and polycaprolactone (Capa 6506, Perstorp UK
Limited). Magnesium stearate (Sandoz, Basel, Switzerland) was
used for lubrication. KombiglyzeVR XR 5mg/500mg (Astra Zeneca,
London, UK) was taken as a reference.
Compaction of core tablet
All excipients were sieved (<500mm) and blended using a Turbula
blender (T2C, W.A. Bachofer, Muttenz, Switzerland) at 32 rpm for
10min. This core formulation was compacted on a Styl'One com-
paction simulator (Medel’pharm, Beynost, France) with a 10mm
Euro B flat punch. Compaction cycle was defined with the follow-
ing speed sections: Filling 2.0 s, upper punch approach 1.5 s, com-
paction 70ms, relaxation 1.0 s, ejection 5.0 s, and tablet selection
700ms. An amount of 520mg core formulation was compacted at
a force set at 17 kN.
Hot-melt granulation
To produce the FCC-PCL composite, hot-melt granulation was car-
ried out on a twin screw hot-melt extruder with perforated die
(Three-Tec, ZE9 20602, Seon, Switzerland). The 5 heat cells were
adjusted to the following temperatures: cell 1: 10 C, cell 2: 50 C,
and cell 3, 4, 5 to 80 C. Feed rate was set between 3.1 and 4.5 g/
min. Twin screws were set at 100 rpm. The extruded product was
cryo-milled with an IKA A11 (IKA, Staufen, Germany) single-speed
hand-mill with cut tooling. The milled product was sieved through
a 500 mm sieve. To analyze the FCC-PCL composite, a deformation
profile was performed with 11.28mm flat Euro D punch using
compaction pressures from 45 to 295MPa, time for compaction
was set to 1.5 s.
Compaction of the TIC
The final compaction of the TIC was carried out with a 13mm
Euro B beveled punch. The cycle was defined with the following
speed sections: Filling 2.0 s, upper punch approach 10.0 s, compac-
tion 70ms, relaxation 0.14 s, ejection 70ms, and tablet selection
700ms. Compaction force was set at 20 kN. Filling height was set
at 9.2mm, the core was centered on the lower punch, and FCC-
PCL composite (<500 mm) was filled in the die manually (see
Figure 1).
In this project, the core tablet was manually placed on the
punch in order to compact it to a TIC device. This process can be
transferred to a standard dry coating production line. This is due
to the fact that the TIC device is produced the same way, only
leaving out the top layer [26]. Centering the core in a dry coated
tablet is a challenge, as we used a beveled punch, this centering
is facilitated which is also possible on a standard production line.
The empty cups for hardness testing were produced in the
same way as the TIC device but instead of a core tablet, a metal
Figure 1. Schematic representation of the TIC manufacturing process. The previously compacted core (a) is centered on the lowered punch into the empty die (white,
b). The tooling is represented in dark gray. The random white circles represent the FCC-PCL composite material (c) that is filled over the core (d). The dark gray circles
represent the compacted FCC-PCL composite material (e). After ejection the TIC (f) is manufactured.
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tablet was used as a template. After compaction, the metal tablet
was removed.
Scanning electron microscopy
Scanning electron microscopy (SEM) pictures were made with a
FEI Nova Nano SEM 230. The samples were sputtered with a
20–40 nm gold layer by a LEICA EM ACE600 double sputter coater.
Compactibility and compressibility
Compressibility of the FCC-PCL composite was investigated using
the Heckel equation (Equation 1) [27]:
ln
1
1 q
 
¼ k  rþ A; (1)
where k is the Heckel parameter (MPa1), r is the compressive
pressure (MPa), q is the density of the tablet (g/cm3), and A is a
constant. Compressive stress was varied between 45MPa and
295MPa. Density of the tablet was calculated according to
Equation 2 [28]:
q ¼ ð
m
pr2hÞ
qtrue
; (2)
where m is the mass of the tablet (g), r is the radius of the tablet
(cm), h is the tablet height and qtrue is the true density of the
material (g/cm3).The yield pressure was calculated by taking the
reciprocal of the Heckel slope [28] (ry ¼ 1k)
In order to investigate compaction susceptibility of the mater-
ial, the modified Heckel equation was used [29]:
r ¼ 1
C
qrc  q 1 qrcð Þ  ln
1 q
1 qrc
  
; (3)
where r is the compressive pressure (MPa), C is a constant
(MPa1), qrc is the critical density (g/cm
3) and q is the relative tab-
let density (g/cm3).
Powder compactibility was investigated by plotting tensile
strength as a function of compressive pressures [12]. Tensile
strengths were calculated according to Equation 4.
rt ¼ 2  Fp  d  h ; (4)
where rt is the tensile strength (MPa), F is the crushing force (N),
d is the diameter (mm) of the round tablets and h the height of
the round tablet (mm).
Information about the deformation of the material under stress
and bonding properties of the material was obtained by calculat-
ing the factors compactibility and compression susceptibility using
Leuenberger equation [12] (Equation 5):
rt ¼ rðtmaxÞ ð1 eðcrqÞÞ; (5)
where rt is the tensile strength, rt max is the tensile strength
when compressive pressure (r) !1 and relative density (q)! 1, c
is the compression susceptibility, and r is the applied compressive
pressure. Data obtained at 45–295MPa were included in the
calculation.
Permeability assessment of compacted material
Porosity, median pore diameter, permeability and tortuosity of the
compacted FCC-PCL material has been obtained through mercury
porosimetry with Auto Pore IV9500 mercury porosimeter
(Micromeritics Instrument, Norcross, GA, USA). Low-pressure
mercury intrusion ranged from 3.59 to 206.64 kPa and during the
high-pressure mercury intrusion the pressure ranged from 206.64
to 206.78MPa.
Pressure difference required to establish a flow through a por-
ous structure of FCC-PCL material is calculated with
Hagen–Poiseuille equation [30]
Dp ¼ v  32ll
d2
(6)
Where, v is the liquid velocity on a porous media (m/s), l is
the dynamic viscosity of liquid (Pas), l is a length of a membrane
(m), and d is a median pore diameter (m).
Stress-strain curve of the mineral-polymer composite
To obtain the stress–strain curve, an additional experiment was
carried out. The molten composite was compressed in a 11 mm
die manually to yield a uniform flat disk and to remove all
entrapped air from the material. After cooling to the room tem-
perature, the disk was subjected for a compressive deformation
stress. For this purpose, the StylOne tablet press was equipped
with 13mm beveled lower punch and a 9 mm upper punch; a
deformation within 10 s was carried out. The resulting force and
punch displacements were recorded and used with Equations 7
and 8 to obtain mean engineering stress (p) and relative strain (E)
[31].
The stress–strain curve of FCC-PCL composite was obtained
with plotting p vs E (see Equations 7 and 8).
p ¼ P  h
p  R2  H ; (7)
E ¼ ln  h
H
; (8)
Where p is the mean stress (Pa), P is the value of the load (N),
h is the gap between upper and lower punch (m), R is the radius
of the upper punch, H is the original height of the sample (m) and
E is the relative strain.
The Young’s modulus is the slope of the fitting of the linear
section of the stress-strain curve.
Drug dissolution from TIC device
Dissolution testing (TIC: n¼ 6; KombiglyzeVR XR: n¼ 3, cores: n¼ 6)
was carried out on SOTAX AT7 Smart (Sotax, Switzerland) con-
nected to a UV-spectrometer (Amersham Biosciences, Ultraspec
3100 pro, UK) with a Sotax CY 7–50 pump (Sotax, Switzerland).
The dissolution profile was measured in water (37 C), USP appar-
atus 2, 50 rpm over 24 h for TIC and KombiglyzeVR XR and 3 h for
the cores, respectively.
The spectrometer was set to 250 nm, and concentrations were
calculated according the following equation: y ¼ 0:0015x þ 0:0102,
R2 ¼ 0:9998.
F2 criterion was calculated according to FDA [32]:
f2 ¼ 50  log 1þ 1n
P
Rt  Ttð Þ2
h i0:5
 100
 
, where Rt is drug
release in % (m/m) at time t of the reference sample and Tt is
drug release in % (m/m) at time t of the test sample, n¼ 145.
Hardness and friability testing
Hardness testing (TIC n¼ 6; core n¼ 6, cup without core n¼ 3,
KombiglyzeVR XR: n¼ 3) was carried out with Dr. Schleuniger Tablet
Tester 8M (Switzerland). Friability (n¼ 10) was assessed using
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Erweka TA200 (Erweka, Germany). Tensile strength was calculated
according to Equation 4 for round tablets and according to
Equation 9 for shaped tablets [33]:
rt ¼ 23
10  F
pD2  2:84 tD 0:126 tW þ 3:15WD þ 0:01
 	
" #
; (9)
where rt is the tensile strength (MPa) and F is the crushing force
(N). For shaped tablet, D is the tablet width, t is the tablet height,
and W is the shaft height (mm).
Results
To produce the FCC-PCL composite, first FCC and PCL were mixed,
followed by hot-melt granulation. During hot-melt granulation,
torque remained constant at 3.21 ± 0.04Nm. Temperatures of cell
3, cell 4, and cell 5 were 80.12 ± 0.66 C, 80.02 ± 2.31 C, and
80.20 ± 3.01 C, respectively. Only the temperatures of cell 3 to 5
were taken into consideration as polymer melting occurred in
these cells. Production of the FCC-PCL composite used to form the
cup did not pose any problems.
After granulation, the product was frozen, milled, and sieved.
Figure 2 shows a SEM picture of the granules with the lamellar
structure of FCC embedded in PCL. Only the granules sized
<500mm were used. The results of Heckel, modified Heckel, and
Leuenberger analysis are shown in Table 1. Figure 3 shows the
Heckel plot, modified Heckel plot, and Leuenberger plot.
The stress-strain curve of the FCC-PCL composite is shown in
Figure 4. The Young’s Modulus, which is represented by a slope of
a linear section 0.02< E< 0.08, is 0.462GPa. (R2¼ 0.987).
The stress–strain curve is characterized by a clear upper yield
point followed by a lower yield point.
The core tablets and cup material were compacted to form the
TIC device with the geometrics as shown in Table 2. Resulting
parameters of the TIC device (i.e., core compacted in the cup), are
shown in Table 2 along with measured parameters of the refer-
ence product (KombiglyzeVR XR). During hardness testing of the TIC,
core and cup were not falling apart. Separately, the hardness of
the cup was also assessed without core tablet and yielded
90.50 ± 4.68N.
Despite the mediocre flowability of the cup material, the flow
of the material under compaction can be characterized as good
for both the slow (10 s) and fast (70ms) compaction cycles. In
both cases (i.e. fast and slow compaction speeds) the cup material
distribution shows homogeneity (forming equally-sized cup walls,
without cracks, ruptures or gaps). An example of compacted cup
material is shown in Figure 5. The results obtained from porosime-
try indicate median pore size diameter of the compacted cup
material 8.9 ± 0.4 nm. According to Hagen–Poiseuille equation for a
Figure 2. SEM picture of the FCC-PCL composite granule (a). Individual components are shown with corresponding arrows (a, b, c). FCC particles remain their shape
and structures which is shown with the comparison pictures of pure FCC [17] (d, e).
Table 1. Compressibility and compactibility parameters for the
FCC-PCL composite
Parameters Values for FCC-PCL composite
Heckel analysis
k (103 MPa1) ± SD 2.65 ± 0.22
A ± SD 2.09 ± 0.04
ry (MPa) 377.36
Adj R2 0.873
Modified Heckel analysis
C (103 MPa1) 0.20 ± 0.14
qrc ± SD 0.847 ± 0.04
Adj. R2 0.940
Leuenberger analysis
rmax (MPa) ± SD 3.44 ± 0.07
c (103MPa1) 19.43 ± 1.11
Adj R2 0.870
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flow through porous membrane [30] the pressure difference to
obtain a liquid velocity of 1mm/hour will require a positive pres-
sure difference between outer surface of the cup and internal
volume of approx. 2mPa.
Figure 6 shows the release profile of TIC and KombiglyzeVR XR
5mg/500mg. The release profile of the TIC was slightly slower
than the profile of KombiglyzeVR XR, showing a linear section
between 200 and 800min. Standard deviations did not exceed
1.33% (m/m) in the case of KombiglyzeVR XR and 2.58% in the case
of the TIC. The f2 test yielded a value of 78.60, hence the dissol-
ution profiles were considered identical.
Discussion
The properties of a novel calcium carbonate-polymer composite
(FCC-PCL) prepared in a hot-melt granulation process were
studied.
The results of compactibility and compressibility assays of FCC-
PCL yielded a set of unique properties. From Heckel analysis, the
value for ry yielded 377.36MPa, which is comparable with that
obtained in a previous study where FCC S03 alone had a yield
pressure of ry¼ 294MPa [16]. The obtained values were higher
than those reported in other studies where plastically deforming
materials showed a yield pressure of 40–135MPa [34]. The reason
for this is the larger range of compressive pressure used in this
study [16]. The relative critical density for FCC-PCL obtained with
modified Heckel analysis (qrc¼ 0.847) is indicating higher compres-
sive stress requirement to form a stable compact compared to
pure FCC particles [29]. From Leuenberger analysis, the value for
rtmax yielded 3.44MPa, which suggests plastic behavior of the
material. For c, a value of 19.43 103MPa1 was found. This
value is high compared to that of FCC S03 investigated in the pre-
vious study and is significantly greater than the value for MCC
(7.56 103MPa1) [16]. Such a value might indicate additional
Figure 3. Heckel plot (a), modified Heckel plot (b), and Leuenberger plot (c) of the FCC-PCL composite. In the plot of modified Heckel no standard deviation is shown
as the values were below 1%. The goodness of fit (adj. R2) is 0.873, 0.94 and 0.97 for the all plots, respectively.
Figure 4. The stress-strain curve of the FCC-PCL composite material with the
upper yield point near E¼ 0.1.
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bonding action of PCL polymer on FCC lamellae. High values of c
indicate plastic behavior and that the maximal tensile strength
can be reached at low compressive pressures [12]. Both values, c
and rtmax, show the good bonding properties of the material [12].
The observed flow properties of the composite particles were
excellent under compaction pressure. During the solidification, no
cracking, rupture, nor gaps formation were observed even at fast
compaction cycles. Such properties suggest a high inner structure
mobility of the FCC-PCL material under a load, which is advanta-
geous for upscaling the production of TIC geometries. Our study
suggest that it is possible to compact this material at speeds com-
parable to those reached on conventional rotary presses and pro-
duce complex geometries such as TIC compacts.
It should be kept in mind that compaction of a pure PCL poly-
mer without a thermoforming is limited because of a relative low
value of a pure PCL Young’s modulus. The Young’s modulus of FCC-
PCL composite material yielded a 2-fold increase compared to a
pure PCL polymer (0.199GPa), suggesting a fast onset of a plastic
deformation phase. The value of 0.462GPa is in agreement with lit-
erature data [35], where the PCL has been combined with different
amounts of hydroxyapatite (HA), which results in an increase of a
Young’s modulus up to 0.48GPa after 20% HA addition. Further
increase of HA admixtures has increased the Young’s modulus up to
0.75GPa at 40% HA. This trend supports our finding that with the
increase of mineral component concentration in a polymer causes
composite material plastic behavior under stress to be reached
much faster. The plastic behavior under a stress is a substantial
requirement for compaction of a pharmaceutical tablet. With the
FCC-PCL composite such requirement can be easily satisfied.
A second important property of a stress–strain diagram of the
FCC-PCL composite is a presence of a lower yield point, which is
often explained as presence of a Cottrel atmospheres in case of a
homogeneous materials such as steels [36]. For the material pro-
posed in this study we can assume an ordering of FCC micropar-
ticles in a PCL matrix under applied loads, supporting high
plasticity of the material. At values around E¼ 0.45 the stress
increases for a second time (see Figure 4) until a suspected rup-
ture. In pure PCL the lower yield point cannot be identified.
The results of the TIC compaction support a sufficient ductility
of the composite material to form stable and robust cup under
compressive stress without damaging the core tablet. These
results were obtained for compaction dwell time of 70ms, which
correspond to 35,000 tablets per hour production scale on rotary
tablet presses.
This new material has demonstrated a feasibility to manufac-
ture a geometry-controlled sustained-release formulation taking
metformin HCl as a model substance. Good compressibility and
compactibility properties of FCC-PCL composite material allowed
to prepare a sustained-release formulation with significantly
reduced concentrations of matrix-forming components. As shown
in Figure 2, the lamellae of the FCC were still present and were
not damaged or clotted by PCL, indicating that the properties of
the FCC were preserved. The lamellae interlocked with each other,
which resulted in stable compacts [16]. The granules were not brit-
tle, that is why freezing before milling was necessary. Another rea-
son for freezing was the fact that energy generated by the milling
process would have melted the PCL forming lumps.
The concentrations of PVA and Carbopol are around 2% of the
total mass. This amount can be considered to be low. In other for-
mulations using e.g. HPMC between 20% and 50% of polymer
were used to achieve sustained release [3].
In order to investigate a mechanical stability and water barrier
properties of the proposed composite material the TIC-metformin
formulation was compared with the commercial product
KombiglyzeVR XR 5mg/500mg. TIC proved to be 203mg lighter
than KombiglyzeVR XR. Hence, drug load of TIC was 8.5% higher
than that of KombiglyzeVR XR. The TIC device was less voluminous
(754.27 ± 3.82mm3) compared to KombiglyzeVR XR (985.7mm3),
Table 2. Parameters of the core, TIC, and kombiglyzeVR XR.
Average Core TIC KombiglyzeVR XR
Weight (mg) 517.46 ± 2.32 994.53 ± 5.67 1197.90 ± 9.87
Diameter (mm) 10.03 ± 0.00 13.06 ± 0.00 9.78 ± 0.02a 19.60 ± 0.02b
Height (mm) 5.36 ± 0.03 5.70 ± 0.03 7.20 ± 0.02
Hardness (N) 127.00 ± 8.63 261.33 ± 15.19 297.33 ± 45.83
Tensile strength (MPa) 1.50 ± 0.11 2.24 ± 0.12 2.22 ± 0.33
Volume (mm3) 423.49 ± 2.16 755.05 ± 4.01 985.7
Friability (%) — 0.00c —
Drug load (%) (m/m) 96.63 50.27 41.73
aWidth of oblong tablet.
bLength of oblong tablet.
cNo mass change was detected.
Figure 5. SEM picture of FCC-PCL composite material after compaction into TIC.
Observable cracks with mean pore diameter of 8.9 nm do not allow liquid to
penetrate intopenetrate TIC in significant amounts.
Figure 6. Dissolution profile of TIC 500mg metformin HCl (O), KombiglyzeVR XR
5mg/500mg () and the metformin core tablets (). The error bars represent
standard deviation, f2 criterion between TIC-metformin HCl and KombiglyzeV
R
XR
was 78.60.
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which makes it easier to swallow. The amount of excipient to con-
trol the release was 20mg; this is 2% (m/m) of the total mass of
the TIC. Due to the fact that only one surface is accessible for the
medium, only a small amount of excipient to control the release is
necessary. This can help in formulation development. During fri-
ability test no mass change was detected. The TIC devices were
stable and showed no breakage or deformation, hence a coating
will not be required. The cup without core tablet was stable with
a hardness of 90.50N, which is not surprising due to the values c
and rtmax indicating good bonding at low compressive stress. As
shown in Figure 5, the connection between core and cup was
tight and hence, no dose dumping is expected. The studied
material show a dense structure with pore sizes lying within
10 nm region. This is not a tight barrier for liquids and a certain
liquid permittivity should always be considered. On the other
hand, an assessment of pressure difference required for a minimal
liquid velocity of 1mm/hour (according to Equation 6 needs a
positive value of 2mPa. This mass transfer does not include any
concentration-driven diffusion for given geometry with one side
open. The cup has good mechanical stability which is supported
by undetectable friability. This shows high stability and density of
the FCC-PCL material and its ability to stabilize the core.
The polymer PCL is biodegradable [37] but even if the cup of
the TIC- device would stay intact it would be excreted in the feces.
On the Swiss market there is a tablet available in a comparable
size, where it is also described that the indigestible matrix will be
excreted [38]. Because in this project a beveled punch was used,
there are also no sharp edges that could harm the intestines.
Irritations or damages to the intestinal tissues are not expected.
Conclusions
Our results suggest that FCC-PCL mixtures have the potential to
become a useful material for successful dosage formulation at an
early stage of drug development. Moreover, the FCC-PCL compos-
ite material can be considered as safe. PCL was previously shown
to be biodegradable [37], and FCC was shown to be safe [39].
Sufficient stress resistance and good compressibility of the
FCC-PCL composite were confirmed by Leuenberger and Heckel
analysis. These characteristics make it possible to use this material
at higher production speeds of 35000 tablets per hour or higher if
necessary. It was important to demonstrate that production of
TIC-device can be made in a single step—excluding core
compaction—with standard equipment. Although industrial-scale
production was not tried with this material, there is no indication
of potential performance hindrance as other geometrically altered
formulations have been proven to be industrially producible [10].
A significant effect on sustaining the release rate due to geometric
constraints, as demonstrated in this study involving metformin HCl
in a TIC device. This may allow simplification of the formulation
work, reduction of matrix components and other excipient con-
centrations, and reduction of size and mass of the tablets. The
advantageous mechanical properties of the studied material are
attributed to the unique properties of FCC due to its high specific
surface and highly developed lamellar structure. In general, this
material and the proposed formulation strategy can find its appli-
cation in other types of geometries and can be instrumental to
develop more complex and specialized delivery devices.
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4 Discussion  
For the heterogeneous population of pediatrics, it is of necessity to provide dosage forms that are 
flexible, age-appropriate and cost effective. Novel strategies to formulate such dosage forms are of 
interest. The research described in this work shows new formulation platforms fulfilling the need to 
serve as a tool to formulate oral dosage forms for children. There is a need for new excipients that 
fulfill several functions at once as the currently available substances are not sufficient. FCC is 
advantageous as it is a co-processed material of two already well known excipients. With the co-
processing, new properties were created by modifying the surface structure. This underlines the 
importance of the microstructure of excipients. The fact, that the functionality of FCC is based on its 
microstructure is beneficial for the use in the pediatric population as it is already known to be safe.  
4.1 The microstructure as a key characteristic 
The microstructure of the FCC particle is the key characteristic for the presented work and the use in 
pediatric formulations. During tablet compaction, the lamellae interlock with each other forming stable 
bonds. When used as ready-to-use granules, it was shown that the disintegrant is distributed within the 
granule and the granule particles do not break under pressure (see Figure 2) [128]. Also, this stability 
roots in the strong bondage between the FCC particles. When processed with hot melt granulation, the 
particles experienced high shear forces and were embedded in the polymer. As shown in Figure 5b on 
the SEM picture, the lamellar structure stays intact, suggesting a high degree of flexibility [129]. 
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Figure 2: The 3D reconstructed X-ray micro tomography data with application of phase retrieval filter 
algorithm of a 9.0% (m/m) moxidectin mini-tablet with a diameter of 2mm [128]. The dark grey substance 
is the drug moxidectin, the light grey shows the granules and the embedded dark grey particles in the light 
grey phase are disintegrant. 
 
4.2 FCC-based ODTs as age-appropriate formulations 
When keeping the developmental physical differences in mind, an ODT is a suitable dosage form for 
children. It fulfills the requirements of an age-appropriate formulation (see section 1.5.1). The ODT 
does not need to be swallowed as a whole due to rapid disintegration upon contact with the saliva. The 
FCC consists of calcium carbonate and calcium phosphate which both are excipients that can be 
considered safe for children [130]. Taste masking and mouthfeel-enhancement was possible. In the 
presented work, artificial sweetener was used in combination with citric acid reacting with sodium 
bicarbonate, creating a tickly feeling in the mouth. The dose can be adapted when used in different 
sub-groups of the pediatric population. The ODTs can be compacted to large tablets or to mini-tablets. 
Like this, a dosing per kilogram of bodyweight is possible without additional formulation work. 
The administration is easy, the ODT can be put on the tongue or in the buccal pouch, this way it is also 
possible to administer the tablet to infants. Also, the administration is not complicated (compared to an 
inhaling device) or in any way culturally inacceptable (compared to suppositories). With an ODT, 
compliance can be enhanced. The child is more likely to be willing to take such a formulation, so the 
risk of administering the medication the wrong way or not at all can be lowered.  
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The presented ODT (5mm diameter, 50mg weight) formulation does not need more liquid to 
disintegrate completely than there is present in the mouth of a child [131]. The mentioned 5mm ODT 
need 0.28ml of saliva for complete disintegration. Literature reports 1.21ml/min stimulated salivary 
flow rate and 0.51ml/min unstimulated salivary flow rate in children of age 3-16 years [132]. 
Considering that citric acid [133] is a stimulant, the stimulated salivary flow rate is more appropriate 
as a comparison. 
The FCC was dry granulated and used for the preparation of ODTs and TOS (see section 4.3). Dry 
granulation did not show reduced compactibility properties after roller compaction [134]. When roller 
compacting FCC with a disintegrant (i.e AcDiSol), the values for Heckel analysis, modified Heckel 
analysis and Leuenberger analysis were comparable to the values proposed in literature [122,131]. 
Therefore, the unique properties are preserved yielding to a ready-to-use granule (ReadyMix) that can 
be further used [135]. The addition of more excipients needed for taste-masking did not change the 
unique compaction behavior of FCC either [131]. There is no evidence that the techniques of taste 
masking are limited to the option chosen in this work. The ReadyMix can also be blended with coated 
taste masked granules or particles prepared through hot melt extrusion. 
4.3 FCC-based TOS as age-appropriate formulation 
Rapidly disintegrating tablets based on FCC disintegrate in the same manner as ODTs. An advantage 
of TOS is the possibility do deliver larger doses than with a formulation that is directly placed in the 
mouth. By using a spoon to disintegrate the TOS in a liquid, a suspension can easily be prepared. This 
in situ prepared suspension can be administered the same ways as conventional suspensions known on 
the market. This can improve the acceptance of a novel stable formulation for the population in 
countries that are used to liquid preparations. The FCC based TOS can be dispersed in water on a 
spoon or in a glass. Due to the fact that the disintegration of the proposed formulation is based on a 
water insoluble swelling disintegrant (AcDiSol) and not containing large amounts of sodium, the 
danger of clinically relevant intakes of sodium is eliminated [3]. Disintegrated TOS on a spoon are 
desired as the volume of liquid to be taken by a child can be reduced. Moreover, infants and elderly 
patients can be treated with TOS. Influences on disintegration time of the TOS in water were found to 
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be independent of the drug load but affected by the disintegrant concentration and FCC concentration 
[136]. Under stressed conditions, it was shown that the disintegration time in water and art.sal. were 
influenced by temperature and humidity [136]. This underlines the importance of storage conditions. 
The content of the investigated TOS was not affected by the stressed conditions. With the used model 
drugs, degradation was not detected in the presence of FCC [136].  
4.4 In vitro disintegration time analysis 
To estimate if the saliva in a child’s mouth is sufficient to ensure complete disintegration of the ODT, 
the developed model provides parameters to understand disintegration kinetics [131]. This approach 
allows to draw meaningful conclusions about the processes taking place in the oral cavity. This 
method to investigate the disintegration time has additional benefits as various disintegration media 
can be used. For example, TOS’ time to disperse in water on a spoon or in a glass can be analyzed. For 
an ODT, artificial saliva can be used to approximate the situation in the mouth. Moreover, for even 
more sophisticated dosage forms used e.g. in a device like the nipple shield delivery system (NSDS) a 
human or bovine milk can be used [137]. The kinetic of the disintegration is governed by two 
processes: the liquid absorption and the disintegration of the wetted mass. These two processes are 
taking place simultaneously. It differs from a kinetic where the tablet first absorbs the liquid and 
subsequently disintegrates [123]. This has the advantage, that the tablet does not swell to the same 
extent and that the liquid can be reused once the particles have been disintegrated. All this information 
cannot be obtained with the conventional method given by the Ph.Eur. It is also not possible to 
accurately measure disintegration time with the conventional method, if it takes only a few 
seconds [123]. 
High dispersibility of the particles provided by TOS and ODTs can be beneficial for the treatment of 
local infections in the gastrointestinal tract because the drug can be evenly distributed [126]. 
4.5 Palatability testing 
In a human panel test, the ODTs based on FCC granules were rated as pleasant by healthy adults. This 
data is necessary to collect before the formulation can be investigated for palatability in a panel test 
involving children. In the presented work the adults were asked for acceptability, therefore preference 
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was not assessed. To ask the questions, a VAS combined with a hedonic scale was used (see Figure 3). 
In addition the extremes of the scales were labeled with the best and the worst answer possible to 
ensure that all volunteers understand the questionnaire [131]. 
 
Figure 3: VAS combined with hedonic scale and possible answers [131]. 
The statistical analysis showed that only in vivo disintegration time and the age of the volunteers was 
normally distributed. The answers to the questions were shifted toward the best possible answers. The 
volunteers reported to some extent a feeling of roughness in the mouth. This is not surprising as the 
FCC granules do not dissolve in the oral cavity and literature shows that humans can feel roughness of 
particles from the size >244µm [138]. Interestingly, in our study the volunteers reported to have a 
pleasant feeling in the mouth. This leads to the conclusion that rough sensation does not particularly 
lead to unpleasant feeling in the mouth [131]. 
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4.6 Drug distribution in mini-tablets 
Tablets based on the ready-to-use granule are shown to be characterized by fast disintegration times. 
This leads to high dispersibility of the particles that can be beneficial for local treatment of 
helminthiasis. In order to ensure equal drug distribution in the gastrointestinal tract, drug distribution 
in the tablet is essential. Therefore, a novel method was applied to investigate drug dislocation within 
FCC-based mini-tablets. It was shown, that it is possible to use synchrotron X-ray micro tomography 
with subsequent analysis to describe the location of the drug voxels inside of the mini-tablets. From 
our four proposed formulations the 9.0% moxidectin formulation showed the best content uniformity. 
This was shown with HPLC analysis as well as with microtomography results. The mini-tablet is a 
suitable dosage form to treat helminthiasis, as low doses are needed. With the mini-tablet, dosing is 
flexible and adjustable for individual patients. 
4.7 Compliance enhanced formulation 
The ODT platform is one among many options to enhance compliance. Another strategy is to simply 
adapt a concept used for adults. The Tablet-In-Cup (TIC) device showed to have sustained release 
comparable to a market product while having less volume and a higher drug load (see Figure 4).  
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Figure 4: Dissolution profile of TIC 500mg metformin HCl (○), Kombiglyze® XR 5mg/500mg (■) and the 
metformin core tablets (Í). The error bars represent standard deviation [129]. 
 
This approach can be used to adapt a formulation to the need of a pediatric formulation. By decreasing 
the size of the TIC, it is also possible to be swallowed by children [3]. No matter which dose needs to 
be delivered, the concept of the TIC stays the same. By using the FCC-PCL composite material, the 
surfaces of the core tablet can be successfully sealed (see Figure 5a) [129]. The FCC-PCL composite 
material shows good compactibility and compressibility and flows very well under pressure. This 
mainly roots in the embedding of the FCC in the polymer. The lamellae are highly flexible, even after 
hot melt granulation they are still intact (see Figure 5b). Therefore, they can still interlock yielding a 
stable TIC.  
This feature also opens options for other dosage forms like abuse deterrent formulations (ADF). 
Moreover, the composite material shows plastic deformation under pressure, which is advantageous 
for formulating ADF. In case of ADFs, polymers are used to prevent manipulation of any kind [139]. 
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Another application could be the use in sustained release formulations [140]. This makes the FCC-
PCL composite material a unique multifunctional excipient.    
a)  b)   
Figure 5: a) SEM picture of FCC-PCL composite material after compaction into TIC. Observable cracks 
do not allow liquid to penetrate into TIC in significant amounts; b) granules with visible lamellar 
structure of the FCC embedded in PCL [129]. 
 
4.8 Simplicity of manufacturing 
With the FCC-based granules, ODTs and TOS can be produced. The process was identical for both 
dosage forms. This makes the FCC a versatile multifunctional excipient. The granule can be blended 
with additional excipient or API without any further granulation or loading steps (see Figure 6). This 
is very advantageous, as the blending step is simpler compared to wet-granulation or loading. All the 
tablets show high physical stability and fast disintegration times. The additional excipients to enhance 
mouthfeel and mask a bad taste, did not change the unique characteristics during compaction of the 
granules. The process chosen to manufacture the granule was roller compaction, it is a continuous 
manufacturing process that is easier to scale up than a batch based process. To get a final formulation 
from the ready-to-use mix, the excipients simply need to be blended together. Blending is an easy step 
that allows fast and efficient formulation development. 
With this knowledge, also other APIs can be admixed to the ready-to-use mix. It was possible to 
produce mini-tablets that had sufficient physical stability and no occurrences of sticking, picking or 
capping during the compaction process. 
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Figure 6: Blending step of the ready-to-use granule with e.g. drug [136]. 
 
4.9 Regulatory aspects 
The excipient FCC consists of two already very well-known excipients[130]. Hence the difference to 
calcium carbonate and calcium phosphate, respectively is based on the lamellar structure on its 
surface. This makes the safety assessment much easier than when a completely novel substance is 
introduced to the market. The ready-to-use granules can be used in TOS or ODTs. This way, they can 
serve as standard platforms to fulfill requirements in a PIP. FCC is on the market in powder form 
under the name Omyapharm and the ready-to-use granule is available under the name Omyapharm 
ODG [141].The Critical Path Initiative (CPI) is a project by the FDA that has its goal to drive 
innovation in drug development [142]. Therefore, it is of need to make the development process itself 
efficient and effective [143]. Our presented formulation platforms are fulfilling these requests, 
moreover, by choosing robust processes, the requirements for the concept quality by design (QbD) are 
met, too [144]. 
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4.10 Application of the developed platform in low and middle income countries 
(LMIC) 
The lack of pediatric formulations is present all over the world, but access and availability are more of 
an issue in LMIC than e.g. in Europe. Therefore, a suitable formulation platform needs to fulfill 
climatic and economical requirements in LMIC. Moreover, it would be ideal to provide a strategy 
where a technology transfer to the country in need can be carried out. The FCC-based ODT platform 
can serve as such. The granules (available on the market [141]) can be blended and tableted using 
basic technological equipment (e.g. conventional blenders and tablet presses). The high physical 
stability of the ODTs does not require any special packaging such as those required for freeze dried 
products [145]. Simple packaging (i.e. blisters or tablets bottles) that keeps the product dry is 
sufficient. Moreover, refrigeration is not required as the ODTs are stable at room temperature.  
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5 Conclusion and Outlook  
We can conclude that FCC is suitable to produce granules for the use in ODT, TOS, as well as in mini-
tablet formulation development. The processes involved in the production of these granules are 
straight-forward and cost-effective. We showed that the microstructure of the FCC is the key 
characteristic for ODT/TOS formulation and is important as a composite-material in geometry 
constrained sustained release formulations. The ODT and TOS formulations fulfill the requirements of 
age-appropriate formulations. Also, the use of the TIC device seems to be a promising tool to enhance 
compliance in the pediatric population. The lamellar structure on the surface of the FCC is the key 
characteristic for both aforementioned formulation platforms. During roller compaction the particles 
are interlocking with each other without losing the good compactibility behavior which is important 
for the subsequent tableting process. The taste masking and the mouthfeel enhancement of the FCC-
based ODT were successful and no unpleasant sensations were detected. The tablets were well 
accepted by the volunteers. The ODTs were rapidly disintegrating while preserving high physical 
stability. The results of the in vitro analysis showed, that the liquid in the human mouth is sufficient 
for complete ODT disintegration.  
No chemical degradation was detected in the studied FCC-based TOS with the two model drugs 
caffeine and oxantel pamoate. There was no influence of humidity, temperature or storage time on 
drug content. However, humidity and temperature influenced disintegration time and hardness. The 
FCC-based TOS platform can be used to manufacture physically stable, fast disintegrating tablets 
when stored in normal conditions (i.e. room temperature, dry condition).  
Drug dislocation in FCC-based mini-tablets was described by using synchrotron X-ray tomography 
followed by Superpixel Image Clustering. This method is a promising tool to describe segregation 
processes in solid oral dosage forms. 
It was shown that the FCC in a FCC-PCL composite material can be used in a TIC device. The use of 
the TIC allowed for reduction of the amount of excipient to use for sustaining the release as well as the 
reduction of size and mass compared to a marketed product.  
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An important next step is the assessment of the acceptability of the FCC-based ODT in children. 
Therefore, the nature of questioning the children needs to be adapted to age and developmental 
capabilities. This is challenging for children at the age of 2-5 years. In this group, using a hedonic 
scale or VAS might not be the optimal method. Therefore, the ease of administration and the 
spontaneous verbal judgement might serve as a better tool. It is important that the assessor is trained, 
able to concentrate as well as to able isolate external factors from the details linked to the assessment 
of the taste [85]. Facts like spitting out the tablet, crying or demanding another one are important 
indices to evaluate acceptability of the FCC-ODT. This includes an interview with the care giver or 
parent in order to classify situations in correlation with everyday life (e.g. a child that does not like 
orange, will not like the ODT, as it includes orange aroma). After successful evaluation of 
acceptability, formulation development for pediatric use can be started. Drugs that are administered in 
low doses can be incorporated in ODTs, whereas e.g. antibiotics can be developed as a TOS. As a next 
step, the formulation has to be tested in vivo in a comparative pharmacokinetic study. The influence of 
physiological differences during childhood can potentially affect bioavailability when the formulation 
is based on FCC (e.g. difference of pH in stomach). 
For the future, both formulations platforms have high potential. These technologies can form the basis 
of the change of the medication dosing in children worldwide. The availability of the FCC on the 
market promotes the application and research in the future. New formulations can be developed, for 
example: Antibiotic drugs can be developed as a TOS using a SnapTab® shape. This is beneficial as 
the dose could then be accurately divided by hand [146]. Considering that Co-Amoxicillin is widely 
used, the amoxicillin and the clavulanic acid can be formulated in two separate tablets, thereby the 
dose and even the ratio of the two drugs are adjustable in field.  
Corticosteroids that need to have adjustable dose regimens to meet the requirements of individual 
therapies can be formulated in ODTs. Possible formulations can be betamethasone 0.5mg or 
prednisolone 5mg. Moreover, an ODT that contains drugs against travel sickness could be developed, 
having the advantage that the medication does not need to be swallowed. 
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Based on the FCC-PCL composite material, formulation development can be done for ADF. This is 
beneficial for dosage forms containing opioids or narcotic actives, as abuse-related manipulation of 
such dosage forms should be prevented. Additionally, the FCC-PCL can yield sustained drug release 
which can be favorable in the treatment of pain. 
The use of FCC-based formulations is not limited to the mentioned field of pediatric age-appropriate 
and compliance enhanced formulations. The knowledge of this work can be adapted for the geriatric 
population as well as patients suffering from conditions that lead to dysphagia. Of course the presented 
platforms can be applied as a replacement for conventional tablet if the API allows it. 
The application of FCC is certainly not confined to the human pharmaceutical field. The use in areas 
like the food industry, water cleaning, fishkeeping, veterinary pharmacy as well as cleaning agents can 
be explored. 
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